Study ID: [REMOVED]
Title: A Randomized, Open-label, Single-center, Single-dose Study to Evaluate the 
Relative Bioavailability of a New Formulation Compared with the Approved 
Formulation of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) and to 
Assess Dose Linearity of the New Formulation in Healthy Subjects
Study Number: TAK-834-1001
Document Version and Date: Final Protocol/Amendment 1; 18-Nov-2021
Certain information within this document has been redacted (ie, specific content is masked 
irreversibly from view) to protect either personally identifiable information or company 
confidential information. Clinical Study Protocol
For non-commercial use only
TAKEDA PHARMACEUTICALS PROTOCOL
A Randomized, Open -label, Single -center, Single -dose Study  to Evaluate the Relative 
Bioavailability  of a New Formulation Compared with the Approved Formulation of 
Recombinant Human Parathy roid Hormone (rhPTH[1- 84]) and to Assess Dose L inearit y of the 
New Formulation in Healthy  Subjects
Study Identifier: TAK-834-1001
Compound: rhPTH(1-84)
Date: 18-Nov- 2021
Version/Amendment 
Number:Final Protocol/Amendment 1
Amendment History:
Date Amendment Number Region
18-Nov-[ADDRESS_372635] of the study.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 2
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372636] OF APPENDICES ..................................................................................................................7
1. STUDY SUMMARY ................................
...............................................................................8
2.STUDY SCHEMATI C................................................................
...........................................15
3.SCHEDUL E OF STUDY PR OCEDURES ............................................................................16
4.INTRODUCTION ..................................................................................................................19
4.1 Background ..............................................................................................................19
4.2 Rationale for the Proposed Study .............................................................................21
4.3 Benefit/Risk Profile ..................................................................................................22
5.STUDY OBJECTIVES AND ENDPOINTS..........................................................................23
5.1 Hypothesis ................................
................................................................................23
5.2 Study  Objectiv es......................................................................................................23
5.2.1 Study  Primary  Objectives ....................................................................................23
5.2.2 Study  Secondary  Objectives ................................................................................23
5.2.3 Study  Exploratory  Objectives ..............................................................................23
5.3 Endpoints ..................................................................................................................24
5.3.1 Primary  Endpoints ...............................................................................................
24
5.3.2 Secondary  Endpoints ...........................................................................................24
5.3.3 Exploratory  Endpoints .........................................................................................24
5.3.4 Additional Endpoints ...........................................................................................24
6. STUDY DESIGN AND DES CRIPTION ...............................................................................26
6.1 Study  Design ................................
............................................................................26
6.2 Dose Escalat ion........................................................................................................28
6.3 Stoppi[INVESTIGATOR_1869] ................................
.........................................................................28
6.4 Rationale for Study Design, Dose, and Endpoints ...................................................28
6.4.1 Rationale of Study  Design ...................................................................................28
6.4.2 Rationale for Dose ................................ ................................ ............................... 29
6.4.3 Rationale for Endpoints .......................................................................................29
[IP_ADDRESS] Pharmacokinetic Endpoints ....................................................................29
[IP_ADDRESS] Safety  Endpoints ................................ ................................ .................... 29
[IP_ADDRESS] 29
[IP_ADDRESS] 29
6.4.4 Future Biomedical Research ................................ ................................ ................ 30
6.4.5 Critical Procedures Based on Study  Objectives: Timing of Procedures ............. 30
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 3
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
6.5 Study  Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters ................................................................................................................30
6.6 Study  Beginning and End/Completion .....................................................................30
6.6.1 Definition of Beginning of the Study ..................................................................30
6.6.2 Definition of End of the Study ............................................................................30
6.6.3 Definition of Study  Completion ..........................................................................30
6.6.4 Definition of Study  Discontinuation ...................................................................31
6.6.5 Criteria for Premature Termination or Suspension of the Study .........................31
6.6.6 Criteria for Premature Termination or Suspension of a Site ...............................31
7.SELECTION AND DI SCON TINUAT ION/WITHDRAWAL OF SUBJECTS ....................[ADDRESS_372637] Replacement ................................................................................................37
8.CLINICAL STUDY MATER IAL MANAGEMENT ............................................................38
8.1 Clinical Study  Drug ..................................................................................................38
8.1.1 Clinical Study  Drug Labeling ..............................................................................38
8.1.2 Clinical Study  Drug Inventory  and Storage ........................................................38
8.1.3 Clinical Study  Drug Blinding ..............................................................................38
8.1.4 Randomization Code Creation and Storage
........................................................38
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure ..................................38
8.1.6 Accountability  and Destruction of Sponsor -Supplied Drugs
..............................39
9. STUDY PROCEDURES
........................................................................................................40
9.1 Administrative Procedures .......................................................................................40
9.1.1 Informed Consent Procedure ................................ ................................ ............... 40
[IP_ADDRESS] Assignment of Screening and Randomization Numbers........................40
[IP_ADDRESS] Study  Drug Assignment .........................................................................40
9.1.2 Inclusion 
and Exclusion ................................ ................................ ...................... 40
9.1.3 Medical History /Demography ................................ ................................ ............. 40
9.1.4 Concomitant Medications................................ ................................ .................... 40
9.2 Clinical Procedures and Assessments ................................ ................................ ......40
9.2.1 Full Phy sical Exam ................................ ................................ .............................. 41
9.2.2 Height and Weight ................................ ................................ ............................... 41
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 4
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
9.2.3 BMI ......................................................................................................................41
9.2.4 Vital Signs ................................
...........................................................................41
9.2.5 12- Lead ECG .......................................................................................................41
9.2.6 Injection Site Evaluation ................................
.....................................................42
9.2.7 Study  Drug Administration .................................................................................42
9.2.8 AE Monitoring .....................................................................................................42
9.2.9 Laborato ry Procedures and Assessments ............................................................43
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................43
9.3 Pharmacokinetics, ..........44
9.3.1 PK Measurements ................................................................................................44
[IP_ADDRESS] Plasma for PK Measurements ................................................................44
9.3.2 45
[IP_ADDRESS] [ADDRESS_372638] AEs ............................................................................................50
10.2 AE Procedures ..........................................................................................................50
10.2.1 Assigning Severit y/Intensity  of AEs ...................................................................50
10.2.2 Assigning Causality  of AEs .................................................................................51
10.2.3 Start Date .............................................................................................................51
10.2.4 End Date ..............................................................................................................51
10.2.5 Pattern of Adverse Event (Frequency ) ................................................................[ADDRESS_372639] AEs, and 
Abnormal LFTs ...................................................................................................52
[IP_ADDRESS] Collection Period ....................................................................................52
[IP_ADDRESS] Reporting AEs ........................................................................................52
[IP_ADDRESS] Reporting SAEs ................................ ................................ ...................... 53
[IP_ADDRESS] Reporting Special Interest AEs ................................ .............................. 54
[IP_ADDRESS] Reporting of Abnormal LFTs ................................ ................................ .54
10.2.9 Safety  Reporting to Investigators, IRBs or IECs, and Regulatory  
Authorities ...........................................................................................................54
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 5
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
11.STATI STICAL METHODS ...................................................................................................55
11.1 Statistical and Analy tical Plans ................................
................................................55
11.1.1 Analy sis Sets .......................................................................................................55
[IP_ADDRESS] PK Set .....................................................................................................55
[IP_ADDRESS] Safety  Set................................................................
................................55
[IP_ADDRESS] 55
[IP_ADDRESS] 55
11.1.2 Analy sis of Demograph y and Other Baseline Characteristics ............................55
11.1.3 PK Analy sis.........................................................................................................55
[IP_ADDRESS] Relative Bioavailability  (Part I  [Relative Bioavailability ])....................56
[IP_ADDRESS] Dose L inearit y (Part II [Dose L inearit y])...............................................56
[IP_ADDRESS] Non-Parametric Anal ysis................................ .......................................56
11.1.4 56
11.1.5 56
11.1.6 Safety  Anal ysis................................
....................................................................56
[IP_ADDRESS] AEs.........................................................................................................57
[IP_ADDRESS] Clinical L aboratory  Evaluation ..............................................................57
[IP_ADDRESS] Vital Signs ..............................................................................................57
[IP_ADDRESS] Other Safet y Parameters .........................................................................57
11.2 Interim Anal ysis and Criteria for Earl y Termination ...............................................57
11.3 Determina tion of Sample Size ..................................................................................57
12.QUALITY CONTROL AND QUALITY ASSURANCE .....................................................59
12.1 Study -Site Monitoring Visits ...................................................................................59
12.2 Protocol Deviations ..................................................................................................59
12.3 Quality  Assurance Audits and Regulatory  Agency I nspections ..............................59
13.ETHI CAL  ASPECTS OF THE STUDY ................................................................................60
13.1 IRB and/or IEC Approval ................................
........................................................[ADDRESS_372640] Information ..................................................................................64
14.1.2 INVESTIGATOR AGREEMENT ......................................................................65
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 6
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372641] of Abbreviations ................................
...........................................................66
15.DATA HANDLING AND RE CORDKEEPI [INVESTIGATOR_1645]...................................................................68
15.1 CRFs (Electronic and Paper)
....................................................................................[ADDRESS_372642] Retention ......................................................................................................68
16.REFERENC ES.......................................................................................................................70
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 7
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372643] OF IN -TEXT TABL ES
Table 1.a Study  Scheme for Part I (Relative Bioavailability ).........................................8
Table 1.b Study  
Scheme for Part II (Dose Linearity )......................................................9
Table 6.a Study  Scheme for Part I (Relative Bioavailability ).......................................26
Table 6.b Study  Scheme for Part II (Dose Linearity )....................................................[ADDRESS_372644] OF IN -TEXT FIGU RES
Figure 1 Study  Schematic (Part I [Relative Bioavailability ])......................................15
Figure 2 Study  Schematic (Part II [Dose L inearity ])...................................................[ADDRESS_372645] Informed Consent ...................................................73
Appendix C Investigator Consent to the Use of Personal Information .............................75
Appendix D Pregnancy  and Contraception ........................................................................76
Appendix E Summary  of Changes from Previous Version ...............................................80
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 8
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
1. STUDY SUMMARY
Nam e of Sponsor:
[COMPANY_005] Development Center Americas, Inc. (TDC Americas)
[ADDRESS_372646]
Lexington, MA [ZIP_CODE]
Telephone: +1 (617) 679 -7000Compound:
rhPTH(1 -84)
Study Identifier: TAK -834-1001 Phase: 1
Protocol Title: A Randomized, Open -label, Single -center, Single -dose Study to Evaluate the Relative 
Bioavailability of a New  Formulation Compared with the Approved Formulation of Recombinant Human 
Parathyroid Hormone (rhPTH[1 -84]) and to Assess Dose Linearity of the New Formulation in Healthy Subjects
Study Design:
This isarandomized, open -label, single -center, two-partstudy toassess therelative bioavailability ofasingle
subcutaneous (SC) dose ofrhPTH(1 -84)administered asthenew formulation (Formulation A;test) andthe
approved formulation (Formulation B;reference) inPart I (Relative Bioavailability )ofthestudy andtoassess
dose linearity ofFormulation AinPart II(Dose Linearity) ofthestudy. Both parts maybeconducted
concurrently .
Part I (Relative Bioavailability)
Part I (Relative Bioavailability) will be conducted as a randomized, tw o-sequence, two -period , crossover design.
Subjects in each treatment period will receive rhPTH(1 -84) as a single 100 μg SC injection administered in the 
mid-thigh as either Formulation A or Formulation B depending on the randomized (1:1) treatment sequence as 
indicated in Table 1.a.
Blood samples for plasma parathyroid hormone (PTH) pharmacokinetics ( PK)and serum calcium and albumin 
concentrations will be collected predose and for 24hours follow ing each rhPTH(1 -84)administration at the time
points delineated in the Schedule of Study Procedures (Section 3).
There w ill be a drug washout of 96 ( ±1)hours betw een the administration of rhPTH(1 -84) in each period.
Table 1.a S tudy Scheme for Part I (Relative Bioavailability)
Treatment 
SequenceN Treatment Period 1Drug Washout
(Hours)Treatment Period 2
1 42 a 96 (±1) b
2 42 b 96 (±1) a
Treatment Definitions: a=100 µg rhPTH(1 -84) Formulation A ; b=100 µg rhPTH(1 -84) Formulation B
Subjects will remain in the clinical research unit (CRU) until completion of the last postdose assessment on 
Day 2 of Treatment Period 2 . If clinically significant findings are observed upon discharge, subjects may either 
be kept in the CRU for observation or return to the CRU for re- evaluation per Investigator’s discretion.
 
Safety and tolerability will be assessed by [CONTACT_3148] -emergent adverse events (TEAEs) including inject ion site 
reaction assessments, laboratory evaluations, physical examinations, 12 -lead electrocardiograms (ECGs), and 
vital signs .
All subjects who received a dose of study drug (including subjects who terminate from the study early) will 
return to the CRU 16(±2) days (return visit) and 32(±2)days (follow -upvisit) after the last study drug
administration for collection of blood to determine if any adverse events ( AEs) have 
occurred since the last study visit.
Part II (Dose Lineari ty)
Part II (Dose Linearity) will be conducted as a randomized, four -sequence, four -period ,crossover design.
Subjects in each treatment period will receive rhPTH(1 -84) Formulation A as a single SC injection administered 
in the mid- thigh at a dose level depending on the randomized (1:1:1:1) treatment sequence as indicated in 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 9
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Table 1.b. If possible, the same location in the same thigh will be used for all treatment periods . If the same thigh 
cannot be used, the alternative mid -thigh may be used.
Blood samples for plasma PTH PK w ill be collected predose and for 24 hours following each rhPT H(1-84) 
administration at the time points delineated in t he Schedule of Study Procedures (Section 3).
There w ill be a drug washout of 48 ( ±1)hours betw een the administration of rhPTH(1 -84) in each period .
Table 1.b S tudy Scheme for Part II(Dose Linearity)
Treatment 
SequenceN Treatment 
Period 1Drug 
Washout
(Hours)Treatment 
Period 2Drug 
Washout
(Hours)Treatment 
Period 3Drug 
Washout
(Hours)Treatment 
Period 4
1 3 c 48 (±1) d 48 ±1 e 48 (±1) f
2 3 d 48 (±1) f 48 ±1 c 48 (±1) e
3 3 e 48 (±1) c 48 ±1 f 48 (±1) d
4 3 f 48 (±1) e 48 ±1 d 48 (±1) c
Treatment Definitions: c=25 µg rhPTH(1 -84); d=50 µg rhPTH(1 -84); e=75 µg rhPTH(1 -84); 
f =200µgrhPTH(1 -84)
Subjects will remain in the CRU until completion of the last postdose assessment on Day 2 of Treatment 
Period 4.If clinically significant findings are observed upon discharge, subjects may either be kept in the CRU 
for observation or return to the CRU for re- evaluation per Investigator’s discretion .
 
Safety and tolerability will be assessed by [CONTACT_304514], laboratory 
evaluations, physical examinations, 12 -lead ECGs, and vital signs.
All subjects who received a dose of study drug (including subjects who terminate from the study early) will 
return to the CRU 1 6(±2) days (return visit) and 32(±2)days (follow -upvisit) after the last study drug
administration for collection of blood to determine if any AEs have occurred since the 
last study visit .
Study Prim ary Objective s:
Part I (Relative Bioavailability) :
To evaluate the relative bioavailability of a new formulation (Formulation A ;test) com pared with the approved 
formulation (Formulation B ;reference ) of rhPTH(1 -84) follow ing the administration of single SC doses of 
100µg rhPTH(1 -84) in healthy subjects. 
Part II (Dose Linearity) :
To assess the dose linearity of the new formulation (Formulation A) of rhPTH(1 -84) following the administration 
of SC doses of 25 µg, 50 µg, 75 µg, and 200 µg rhPTH(1 -84) in healthy subjects. 
Study Secondary Objectives:
Part I (Relative Bioavailability) :
To assess the safety and tolerability of SC injections of rhPTH(1 -84) administered as Formulation A and 
Form ulation B in healthy subjects.
Part II (Dose Linearity):
To assess the safety and tolerability of SC injections of rhPTH(1 -84) administered as For mulation A in healthy 
subjects.
Study Exploratory Objectives:
 
 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 10
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372647] Population: Healthy male and female subjects aged 1 8to 65 years ,inclusive, at screening. Body 
mass index (BMI) 18. 5-30.0 kg/m2, inclusive, at screening .
Attempts will be made to enroll at least 20% of each sex in each study part .
Planned Number of Subjects:
Part I (Relative Bioavailability ):
Approximately 84subjects ( 42subjects per 
sequence) will be enrolled to ensure at least 
76subjects complete Study Part I .
Part II (Dose Linearity) :
Approximately 12 subjects ( 3subjects per sequence ) 
will be enrolled to ensure at least 8 subjects 
complete Study Part II .Planned Number of Sites:
1
Dose Levels:
Part I (Relative Bioavailability ):
a: 100 µg rhPTH(1 -84) Formulation A (Test)
b: 100 µg rhPTH(1 -84) Formulation B (Reference)
Part II (Dose Linearity) :
c: 25 µg rhPTH(1 -84) Formulation A
d: 50 µg rhPTH(1 -84) Formulation A
e: 75 µg rhPTH(1 -84) Formulation A
f: 200 µg rhPTH(1 -84) Formulation ARoute of Adm inistration:
SC
Duration of Treatm ent:
Part I (Relative Bioavailability) :
Single -dose on Day 1 of each period w ith 
2treatment periods.
Part II (Dose Linearity) :
Single -dose on Day 1 of each period w ith 
4treatment periods.Planned Study Duration :
Part I (Relative Bioavailability) :
Approximately 58days including screening period and 
follow -up.
Part II (Dose Linearity) :
Approximately 60days including screening period and 
follow -up.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 11
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Criteria for Inclusion:
Subjects must fulfill the following inclusion criteria to be eligible for participation in the study:
1.Healthy, adult, male or female, [ADDRESS_372648] 20% of each sex in each study part .
2.Continuous non -smoker who has not used nicotine containin g products for at least [ADDRESS_372649] self -reporting.
3.BMI ≥18.5 and ≤30.0 kg/m2at screening.
4.Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, 
vital signs or ECGs, as deemed by [CONTACT_304515]:
Serum calcium, PTH, phosphate, and magnesium within laboratory normal limits at screening and 
check
-in.
Vitamin D ( 1,25(OH) 2D3) levels betw een lower limit of normal and up to 1.5 x upper limit of normal 
(ULN).
Seated blood pressure is ≥89/49 mmHg and ≤139/89 mmHg at screening.
Seated pulse rate is ≥40bpm and ≤99bpm at screening.
QT interval corrected for heart rate using Fridericia’s formula (QTcF) interval is ≤450 msec (males) or 
≤470 msec (females) or ECG findings considered normal or not clinically significant by [CONTACT_304516] g.
Estimated creatinine clearance ≥80 mL/minute at screening.
5.Agrees to comply with any applicable contraceptive requirements of the protocol as detailed in Appendix D.
6.Understands the study procedures in the Informed Consent Form (
ICF), be able to voluntarily provide 
written, signed, and dated informed consent, and be w illing and able to comply with the protocol.
Criteria for Exclusion:
Subjects must not be enrolled in the study if they meet any of the following criteria: 
1.Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit 
or expected during the conduct of the study in the opi[INVESTIGATOR_304495] .
2.History or presence of clinically significant medical or psychiatric condition or disease in the opi[INVESTIGATOR_47338].
3.History of any hematological, hepatic, respi[INVESTIGATOR_696], cardiovascular, renal, neurological or psychia tric disease, 
gall bladder removal, or current or recurrent disease that could affect the action, absorption, or disposition 
of the study drug, or clinical or laboratory assessments.
4.Subjects who are at increased baseline risk for osteosarcoma such as subj ects w ith Paget’s disease of bone 
or unexplained elevations of alkaline phosphatase (ALP), hereditary disorders predisposing to osteosarcoma 
or a prior history of external beam or implant radiation therapy involving the skeleton.
5.History of any illness tha t, in the opi[INVESTIGATOR_25279], might confound the results of the 
study or poses an additional risk to the subject by [CONTACT_47361].
6.History or presence of alcoholism or drug abuse, in the opi[INVESTIGATOR_689] o r designee, within the 
past [ADDRESS_372650] dosing.
7.Male subjects who consume more than 21 units of alcohol per w eek or 3 units per day. Female subjects who 
consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit=1 bee r or 1 w ine 
(5oz/150 mL) or 1 liquor (1.5 oz/40 mL) or 0.75 oz alcohol).
8.Positive urine drug or alcohol results at screening or check -in.
9.History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
10.History of abnormalities of calcium homeostasis including hyperparathyroidism, hypoparathyroidism, 
hyperthyroidism, Cushing’s syndrome, hypercalcemia, hypocalcemia, osteoporosis, or any other calcium 
disorder.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 12
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372651] or who are lactating.
12.Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen 
(HBsAg) ,or hepatitis C virus (HCV).
13.Has tattoo(s) or scarring at or near the site of injection or any other condition which may interfere with 
injection site examination, in the opi[INVESTIGATOR_25279].
14.Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine 
withdrawal headaches. A unit of caffeine is contained in the following items: one 6oz (180 mL) cup of 
coffee, two 12 oz (360 mL) cans of cola, one 12 oz cup of tea, three 1 oz (85 g) chocolate bars.
15.Prior screen failure, randomization, participation, or enrollment in this study or prior exposure to any 
exogenous PTH, PTH fragments or an alogs 3 months prior to dosing with rhPTH(1 -84).
16.Unable to refrain from or anticipates the use of any medication or substance (including prescription or 
over-the-counter, vitamin supplements, natural or herbal supplements) as indicated in Section 7.3 (Excluded 
Medication, Supplements, and Dietary Products) for the prohibited time period.
17.Has been on a diet incompatible w ith the study diet or had any s ubstantial changes in eating habits, in the 
opi[INVESTIGATOR_25279], within the [ADDRESS_372652] blood collection or dosing, whichever is 
later, in the previous study to Day 1 of Treatment Period 1 of the current study.
Main Criteria for Evaluation and Analyses:
The primary endpoint sof the study :
Parts I (Relative Bioavailability) and II (Dose Linearity) :
The follow ingPK param eters for baseline -adjusted plasma PTH concentration sfor each treatment will be 
derived to evaluate relative bioavailability (Part I) and dose linearity (Part II):
Area under the plasma concentration -time curve from time zero to time of the last quantifiable 
concentration (AUC last)
Area under the plasma concentration -time curve from time zero to infinity (AUC ∞)
Maximum observed plasma concentration (C max)
The secondary endpoints will be assessed through evaluation of the following parameters: 
Thefollow ing safety endpoints will be recorded for both Part I (Relative Bioavailability) and Part II (Dose 
Linearity) :
Number, severity, seriousness, and causality of treatment -emergent adverse events ( TEAEs )
Changes in vital signs, ECGs, and laboratory results (hematology, chemistry, and urinalysis) from 
baseline.
 
 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 13
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Additional Endpoints :
Parts I (Relative Bioavailability) and II (Dose Linearity) :
The follow ing additional PK parameters will be estimated for unadjusted and baseline- adjusted plasma PTH 
concentration sfor each single -dose treatment for each treatment regi men:
The area under the curve from the last quantifiable concentration to infinity, expressed as a percentage 
of AUC (AUC extrap %)
Time of first occurrence of C max(tmax)
Time of the last measurable concentration (t last)
The follow ing additional PK parameters will be computed for unadjusted plasma PTH concentration sfor each 
treatment:
Area under the plasma concentration -time curve from time zero to time of the last quantifiable 
concentration (AUC last)
Area under the plasma concentration -time curve from time zero to infinity (AUC ∞)
Maximum observed plasma concentration (C max)
Term inal disposition phase half -life (t 1/2z).
Statistical Considerations:
Pharm acokinetics:
Part I (Relative Bioavailability) :
The baseline- adjusted plasma PK parameters of the different formulations of rhPTH(1 -84) will be compared for 
the relative bioavailability assessment. A linear mixed -effects model for crossover designs w ill be used on the 
natural log (ln) -transformed AUC last, AUC , and C max. The 90% confidence intervals (CIs) for the central value 
ratios of AUC and C maxbetween the test and reference formulations will be constructed based on the 90% CI sof 
the difference in the least -squares means (LSMs) on the log scale.
Part II (Dose Linearity) :
Apparent dose linearity of PK parameters (selected baseline -adjusted AUC and C maxparameters ) will be assessed 
graphically.
Safety:
TEAEs will be tabulated by [CONTACT_304517]. Summary statistics for vital signs, safety 12 -lead ECGs, and 
laboratory assessments will be computed and provided.
 
 
 
 
 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 14
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Sample Size Justification:
Part I (Relative Bioavailability) :
The sample size of 76subjects w as calculated to achieve 90% CI around the geometric mean ratio of the test and 
reference formulations within the limits of 0.[ADDRESS_372653] to reference ratio was 
assumed to be 0.93, and 90% target pow er was used for the sample size determination. The intra -subject 
coefficient of variation (ISCV) w as assumedto be 32.2 %, the upper end of the tw o-sided 50% confidence limit 
of the ISCV for Cmaxestimated in study SHP634 -103(the ISCV observed in study SHP634 -103 w as higher for 
Cmaxthan for AUC) .Part I (Relative Bioavailability) will enroll 84subjects to allow  for up to eight dropouts.
Part II (Dose Linearity) :
The sample size for Part II (Dose Linearity) is not based on any statistical considerations but is considered 
sufficient for dose linearity evaluation. Part II ( Dose Linearity)will enroll [ADDRESS_372654] 
8subjects complete .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 15
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
2. STUDY SCHEMATIC
Figure 1 Study Schematic (Part I[Relative Bioavailability ])
Pretreatm ent Treatm ent Periods 1 -2 (a)Discharge 
(b)Return 
Visit 
(c)Follow up 
(c)
ScreeningPredose 
AssessmentsDosing and 
Study 
AssessmentsSafety and 
PK 
AssessmentsSafety  Safety  
Day -[ADDRESS_372655] 
treatment 
period16(±2) days 
after last 
dose32(±2) days 
after last 
dose
Confinement ( d) 
(a) There w ill be a w ashout period of 96 (±1) hours betw een rhPTH(1 -84) dosing in each treatment period .
(b)If clinically significant findings are observed upon discharge, subjects may either be kept in the CRU for 
observation or return to the CRU for re- evaluation per Investigator’s discretion .
(c) All subjects who received a dose of study drug (including subjects who terminate from the study early) will 
return to the CRU 1 6(±2) days (return visit) and 32(±2)days (follow -upvisit) after the last study drug
administration for collection of blood  to determine if any AEs h ave occurred since the last 
study visit .
(d) Subjects will start the confinement on Day -1 of Treatment Period 1 and remain confined until Day 2of 
Treatment P eriod 2.Subjects may be admitted earlier for Coronavirus disease 2019 ( COVID -19)testing not rel ated 
to study protocol as per CRU requirements. 
Figure 2 Study Schematic (Part II [Dose Linearity] )
Pretreatm ent Treatm ent Periods 1 -4(a) Discharge (b)Return 
Visit (c)Follow up 
(c)
ScreeningPredose 
AssessmentsDosing and 
Study 
AssessmentsSafety and 
PK 
AssessmentsSafety  Safety  
Day -[ADDRESS_372656] 
treatment 
period16(±2) 
days after 
last dose32(±2) 
days after 
last dose
Confinement ( d) 
(a) There w ill be a washout period of 48 (±1) hours betw een rhPTH(1 -84) dosing in each treatment period.
(b)If clinically significant findings are observed upon discharge, subjects may either be kept in the CRU for 
observation or return to the CRU for re- evaluation per Inves tigator’s discretion .
(c) All subjects who received a dose of study drug (including subjects who terminate from the study early) will 
return to the CRU 1 6(±2) days (return visit) and 32(±2)days (follow -upvisit) after the last study drug
administration for collection of blood to determine if any AEs have occurred since the last 
study visit .
(d) Subjects will start the confinement on Day -1 of Treatment Period 1 and remain confined until Day 2 of 
Treatment Period 4. Subjects may be admitted earlier for COVID -19 testing not related to study protocol as per 
CRU requirements.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 16
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
3. SCHEDULE OF STUDY PROCEDURES
Study Procedures
SaStudy Days in Each Treat ment PeriodbEOT
or 
ETcFUd
Days → -1 1 216 
(±2)d32 
(±2)d
Hours → C-Ie-1 -0.5 -0.25 0 11.25 1.5 22.5 3 4 6 8 12 16f24
Minutes → 5 10 20 30 45
Admi nistrative 
Procedures
Informed Consent X
Inclusion/Exclusion 
CriteriaX X
Demographics and 
Medical HistoryX
Safety Evaluations
Full Physical 
Examinationg X X X
Height X
Weight X X X
12-lead Safety ECGhX X XiX X X X X
Vital Signs (PR and BP)jX X XiX X X X X
Vital Signs (T) X X X X X X X
Vital Signs (RR) X X
Hem, Serum Chem, and 
UAX X Xi, kX X
TSH and free T4 X
Serum Pregnancy Test 
(♀only)X X X
Serum FSH ( ♀only) X
Serum PTHlX
Serum Vitamin D X
Urine Drug and Alcohol 
ScreenX X
HIV/Hepatitis Screen X
AE MonitoringmX X X X
ConMeds Monitoring X X X X
Study Drug 
Administration / PK/
Randomization X
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 17
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Study Procedures
SaStudy Days in Each Treat ment PeriodbEOT
or 
ETcFUd
Days → -1 1 216 
(±2)d32 
(±2)d
Hours → C-Ie-1 -0.5 -0.25 0 11.25 1.5 22.5 3 4 6 8 12 16f24
Minutes → 5 10 20 30 45
rhPTH(1 -84) 
Administrationn X
Blood for PTH PK X X X X X X X X X X X X X X X X X X X X
Other Procedures
Admission in the CRU X
Discharge from the CRUpX
Visits X X X
aWithin [ADDRESS_372657] study drug administration.
bFor Part I (Relative Bioavailability) , there will be a washout period of 96 (±1)hours between doses. For Part II (Dose Linearity) , there will be a washout period
of 48 (±1)hours betw een doses.
cTo be perform ed at the end of Treatment Period 2 for Part I (Relative Bioavailability) and end of Treatment Period 4 for Part II (Dose Linearity), or prior to 
early termination from the study. Assessments scheduled for both Day 2 and EOT/ET will not be conducted twice.If clinically significant findings are observed 
upon discharge, subjects may either be kept in the CRU for observation or return to the CRU for re- evaluation per Investigator’s discretion .
dAll subjects who received a dose of study drug (including subjects who terminate from the study early) will return to the CRU 1 6(±2) days (return visi t) and 
32(±2)days (follow -upvisit) after the last study drug administration for collection of blood to determine if any AEs have occurred 
since the last study visit .
eSubjects will be admitted to the CRU on Day -1of Treatment Period 1, at the time indicated by [CONTACT_47365]. Subjects may be admitted earlier for COVID -19 
testing not related to study protocol as per CRU requirements .
fThe 16 -hour postdose may be on either Day 1 or Day 2, depending on the time of dosing on Day 1.
gFull physical examinations will be performed at scheduled time points. Symptom driven physical examinations may be performed at the Investigator’s or 
designee’s discretion.
h12-lead ECG should be performed within ±[ADDRESS_372658] 5 minutes pri or to collecting the ECG
i A ssessments should be performed within ~[ADDRESS_372659] 5 minutes. Postdose assessments should be performed within a window of ±[ADDRESS_372660] void of the day (provided it is predose) but may be outside the 30 -minute window  if necessary.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 18
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372661] for approximately 8 hours prior to dose administration in each treatment period for both Part 
I (Relative Bioavailability) and Part II (Dose 
Linearity) and continu e fasting through at least 2 hours after administration of rhPTH(1 -84).In each study part, treatment administration in consecutive 
treatment period (ie ,Treatment Period 2 in Part I and Treatment Periods 2, 3, and 4 in Part II) w ill be administered at the same time of day ( ±1 hour) as 
treatment administration i n Treatment Period 1.
pSubjects will remain in the CRU until completion of the last postdose assessment on Day 2 of Treatment Period 2 (Part I [Relative Bioavailability] ) or 
Treatment Period 4 (Part II [Dose Linearity] ).
Abbreviations: ♀ =Females,  AE=Adverse events, BP =Blood pressure, C -I =Check -in, Chem =Chemistry, 
ConMeds =Concom itant medication, COVID -19=Coronavirus disease 2019, CRU =Clinical research unit, ECG =Electrocardiogram, 
EOT/ET=End-of-Treatment sor early termination, FSH =Follicle -stimulating hormone, FU =Follow -up, Hem =Hem atology , HIV =Human 
immunodeficiency virus, PK=Pharm acokinetics, PR=Pulse rate, Preg =Pregnancy, PTH= Parathyroid hormone ,RR=Respi[INVESTIGATOR_862], S =Screening, T =Temperature, T4=Thyroxine, TSH =Thyroid stimulating hormone, UA=Urinalysis.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 19
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
4. INTRODUCTION
4.1 Background
Parathy roid hormone ( PTH )is synthesized and secreted by  [CONTACT_304518] p hosphate homeostasis in humans (Brown, 1994; 
Silver and Kronenberg, 1996 ).Endogenous PTH is secreted in response to decreased plasma 
calcium and acts to restore normocalcemia through actions on kidney  and bone, by [CONTACT_304519], both from the rapi[INVESTIGATOR_2478] y 
exchangeable calcium pool and by  [CONTACT_304520]. PTH also regulates 
the activity  of the 25 -hydroxy vitamin D -1α-hydroxy lase enzy me, which stimulates the 
conversion of 25- hydroxy vitamin D to the active form of vitamin D, 1,25 -dihydroxyvitamin D 3
[1,25(OH) 2D3; calcitriol] which in turn increases intestinal calcium and phosphate absorption.
In hypoparath yroidism, impaired endogenous PTH secretory  capacit y results in chronic 
hypocalcemia and hy perphosphatemia, hy percalciuria, low 1,25(OH) 2D3levels, decreased 
intestinal calcium absorption, and low bone turnover. Depending on its severity , chronic 
hypocalcemia can be associated with increased neuromuscular irritability , impaired cognitive 
function, mood disorders, seizures, cataracts, dry  rough skin, coarse brittle hair, alopecia, and 
abnormal dentition. The low bone turnover leads to increased skeletal mineralization and high 
bone mineral densit y (Goltzman and Cole, 2006) . Current therapi[INVESTIGATOR_53301] h ypoparath yroidism 
include calcium and calcitriol/1α -calcidol; the primary  goal of treatment is to control sy mptoms 
of hy pocalcemia while minimizing complications (Shoback, 2008 ).
Human recombinant parathy roid hormone [ rhPTH(1- 84)] has an identical amino acid sequence 
as the endogenous human 84 -amino-acid hormone. 
rhPTH(1 -84) (Natpara®) received orphan designation for the treatment of hy poparathy roidism in 
the US in 2007, followed by  [CONTACT_304521](1 -84) (Natpara®) as an adjunct to calcium and 
vitamin D to control hy pocalcemia in patients with hy poparathy roidism by [CONTACT_33438] (FDA) in 2015. 
rhPTH(1 -84) was granted marketing authorization on 24 April 2006 in the European Union (EU) 
for the therapeutic indication, “Treatment of osteoporosis in postmenopausal women at high risk 
of fractures,” which was later retracted b y the owning compan y for commercial reasons. Orphan 
designation for rhPTH(1 -84) for the treatment of hypoparath yroidism was granted in the EU in 
2013. rhPTH(1- 84) was also granted approval as an adjunctive treatment of adult patients with 
chronic h ypoparath yroidism who cannot be adequately  controlled with standard therapy  alone, 
by [CONTACT_304522] 2017, under the commercial name [CONTACT_304549]®.
Clinical summary
Up to Nov 2020, 16 clinical studies were conducted in which s ystemic concentrations of 
PTH(1- 84) were measured following administration o f rhPTH(1 -84). In [ADDRESS_372662] of the studies in healthy  subjects 
were single -dose investigations. PK and PD measurements were also made after 7 day s, 
12months, and up to 18 months of daily  dosing in subjects with hy poparathy roidism or 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 20
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372663] studies. The site of SC administration 
was either the thigh or abdomen across all studies, but was restricted to the thigh for all studies in 
subjects wi thhypoparathy roidism. Four studies specificall y investigated the PK/PD profiles in 
subjects with hypoparathy roidism.
Pharmacokinetics and Pharmacod ynamics
The PK of PTH(1 -84) following SC administration of rhPTH(1 -84) in the thigh was similar in 
normal subjects, in postmenopausal women with or without osteoporosis, and in subjects with 
hypoparathy roidism. When injected in the thigh, the PK of PTH(1-84) is linear and dose 
proportional over a dose range of 50to 100μg and the response is reproducible acro ssstudies.
Administration to the thigh as opposed to the abdomen showed the same rapid initial increase in 
PTH concentrations, but with a lower peak level. The second peak concentration for the injection 
into the thigh was also lower than that for injecti on into the abdomen. Despi[INVESTIGATOR_304496], the amount of rhPTH(1- 84) absorbed (s ystemic exposure) was slightl y lower following
SC injection in the thigh.
In Stud y CL1-11-013, the mean half- life was about 1.5 hours for SC injection.
In Stud y CL1-11-007, plasma concentrations of PTH approached baseline levels by  12 hours 
after dosing with both SC injection into the abdomen or thigh, however, the serum calcium 
profiles were different. The PD profile of dosing in the thigh showed a more -sustained increa se 
in calcium levels (return to baseline in 24 hours) as compared to the abdomen (return to baseline 
in ±16 hours) Therefore, the thigh is the preferred administration site in the treatment of patients 
with hy poparathy roidism.
Multiple SC dosing of rhPTH(1 -84) in the thigh for 7 day s in health y subjects showed that the
plasma PTH(1- 84) concentration- time profiles on the first and seventh day were similar. The
plasma concentration data from the long -term studies in postmenopausal osteoporotic women
and in subjects with hy poparathy roidism showed that there is no apparent change in the PK of 
PTH after up to 15 months of daily  therapy .
In an open -label study , 7 subjects with hy poparathy roidism received rhPTH(1
-84) 50 μg in the
thigh followed 7 day s later by  a 10 0-μg SC dose. Both doses provided a 24 -hour calcemic
response. There was a dose
-related increase in serum calcium levels, with maximum mean
increases (approximately 0.5 to 0.8 mg/dL) observed at 12 hours. rhPTH(1 -84) administration 
resulted in a substantial decrease in serum phosphate by  [CONTACT_304523] y increasing urinary  phosphate 
excretion, whereas calcitriol administration had little effect on urinary phosphate and tended to 
increase serum phosphate. As a result, rhPTH(1 -84) administration decreased w hereas calcitriol 
increased the serum calcium- phosphate product, an important determinant of soft- tissue 
calcification. Serum 1,25(OH) 2D3increased to peak levels at 8 to 12 hours after rhPTH(1 -84) 
administration.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 21
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Safety
Completed sponsor -initiated studies for the treatment of hy poparathy roidism include 
CL1-11- 040 (REPL ACE), PAR -C10-007 (RELAY), PAR -C10-009 (REPEAT), PAR -C10- 008 
(RACE), SHP634 -101 (PARALLAX) , SHP634- 402, and SHP634 -404. Ongoing 
sponsor -initiated studies in subjects with hy poparathy roidism i nclude PAR -R13-001 
(PARADIGHM) and SHP -634-401.
A review of safety  data across the hy poparathy roidism program to date indicated that 
rhPTH(1 -84) administered in the dose range of 25 to 100 μg SC once dail y (QD) is safe for use 
for the treatment of h ypopara thyroidism. Very  common adverse drug reactions (ie, reported in 
≥10% of subjects) include hy pocalcemia, hy percalcemia, headaches, hy poesthesia, paresthesia, 
diarrhea, nausea, vomiting, arthralgia, and muscle spasms. Common adverse drug reactions 
(ie,
reported in ≥1% of subjects, but <10% of subjects) include h ypomagnesemia, tetan y, upper 
abdominal pain, anxiety , insomnia, palpi[INVESTIGATOR_814], cough, muscle twitching, musculoskeletal pain, 
myalgia, neck pain, pain in extremity , hypercalciuria, pollakiuria, ast henia, chest pain, fatigue, 
injection site reactions, thirst, anti -PTH antibody  positive, decrease in 
blood 
25-hydroxy cholecalciferol levels , decrease in vitamin D levels , somnolence, and h ypertension.
There was no suggestion that rhPTH(1- 84) causes drug
-induced liver injury in humans. There 
were no renal -related AEs or abnormalities in renal function tests or urinalysis tests in clinical 
studies apart from changes expected from the mechanism of action of rhPTH(1 -84). Despi[INVESTIGATOR_304497], treatment 
with rhPTH(1- 84) did not result in worsening of hy percalciuria.
Potential risks include those effects which are extensions of the pharmacologic actions of PTH
including h ypercalcemia.
Refer t o the Investigator’s Brochure (IB) for detailed background information on 
rhPTH(1 -84) (rhPTH(I - 84) Investigator’s Brochure, Edition 11, 02 November 2020).
4.2 Rationale for the Proposed Study
A new formulation of rhPTH(1- 84) has been developed to reduce the oc currence of at ypi[INVESTIGATOR_304498]. The purpose of this study  is to evaluate the 
PK of the new formulation in two parts:
Part I (Relative Bioavailability )will assess the relative bioavailability of the new formulation 
(Formulation A; test) compared with the approved formulation (Formulation B; reference) of 
rhPTH(1 -84) following single -dose SC administration at 100 µg .
Part II (Dose L inearity ) will assess the dose- linearity  of Formulation A follow ing single SC 
administrations in the dose range of 25 µg to 200 µg rhPTH(1- 84).
Utilizing the relative bioavailability  of Formulation A with respect to Formulation B at the 
100µg dose strength (Part I [Relative Bioavailability ]) and the dose -exposure char acteristics of 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 22
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Formulation A, evaluated over a dose range of 25 µg to 200 µg (Part II [Dose Linearit y])
,will 
enable extrapolation of the relative bioavailability atdifferent dose levels.
4.3 Benefit/Risk Profile
The initial therapeutic dose of rhPTH(1 -84) is 50 µg QD, with a maximum recommended dose 
of 100 µg QD (Natpara® [parathy roid hormone], 2020) . In the single ascending dose study  
PBR -930811, doses up to 5.0 µg/kg (equivalent to 350 µg for a 70 kg adult) were found safe and 
well tolerated (rhPTH(I -84) Investigator’s Brochure Edition 11, 02 November 2020). The single 
doses of rhPTH(1 -84) administered in this study  are well below the highest safe and well 
tolerated doses and are not expected to pose any risk to the subjects .
There will be no direct health benefit for study  subjects from receipt of study  drugs. An indirect 
health benefit to the healthy  subjects enrolled in this study  is the free medical tests received at 
screening and during the study .
The inclusion and exclusion criteria, screening, and safet y monitoring practices employed b y this 
protocol (ie, 12 -lead ECG, vital signs, injection site reaction assessments, laboratory  tests, AE 
questioning, and ph ysical examination s) are adequate to protect the subject’s safet y and should 
detect all TEAEs.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 23
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
5.
STUDY OBJECTIVES AND ENDPOINTS
5.1 Hypothesis
Not applicable
5.2 Study Objectives
5.2.1 Study Primary Objective s
Part I (Relative Bioavailability ):
To evaluate the relative bioavailability  of a new formulation (Formulation A ;test) compared 
with the approved formulation (Formulation B ;reference ) of rhPTH(1- 84) following the 
administration of single SC doses of 100 µg rhPTH(1- 84) in healthy  subjects.
Part II (Dose L inearity ):
To assess the dose linearity  of the new formulation (Formulation A) of rhPTH(1 -84) following 
the administration of SC doses of 25 µg, 50 µg, 75 µg, and 200 µg rhPTH(1 -84) in health y 
subjects.
5.2.2 Study Secondary Objective s
Part I (Relative Bioavailability ):
To assess the safet y and tolerability of SC injections of rhPTH(1 -84) administered as 
Formulation A and Formulation B in health y subjects.
Part II (Dose Linearity ):
To assess the safet y and tolerability of SC injections of rhPTH(1 -84) administered as 
Formulation A in health y subjects.
5.2.3 Study Exploratory Objective s
 
 
 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 24
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
5.3 Endpoints
5.3.1 Primary Endpoint s
Parts I (Relative Bioavailability ) and II (Dose Linearity )
:
The following PK parameters for baseline -adjusted plasma PTH concentration sfor each 
treatment will be derived to evaluate relative bioavailability (Part I) and dose linearit y (Part II):
AUC last
AUC ∞
Cmax
5.3.2 Secondary Endpoints 
The following safet y endpoints will be recorded for both Part I (Relative Bioavailability )and 
Part II (Dose L inearity ):
Number, severity , seriousness, and causality  of TEAEs
Changes in vital signs, ECGs, and laboratory  results (hematology , chemistry , and urinal ysis) 
from baseline.
5.3.3 Exploratory Endpoints
 
5.3.4 Additional Endpoints
Parts I (Relative Bioavailability ) and II (Dose Linearity) :
The following additional PK parameters will be estimated for unadjusted and baseline -adjusted 
plasma PTH concentration sfor each single -dose treatment regimen:
AUC %extrap
tmax
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 25
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
tlast
The following additional PK parameters will be computed for unadjusted 
plasma PTH 
concentration sfor each treatment:
AUC last
AUC ∞
Cmax
t1/2z
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 26
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
6. STUDY DESIGN AND DESCRIPTION
6.1 Study Design
This isa randomized, open -label, single -center, two-partstudy toassess therelative
bioavailability of asingle SCdose ofrhPTH(1 -84) admini stered asthenew formulation
(Formulation A;test) andtheapproved formulation (Formulation B;reference) inPartI 
(Relative Bioavailability )
ofthestudy andtoassess dose linearity ofFormulation AinPartII
(Dose Linearity ) ofthestudy .Both parts may be conducted concurrentl y.
Part I (Relative Bioavailability )
Part I (Relative Bioavailability )will be conducted as a randomized, two -sequence, two -period ,
crossover design.
Subjects in each treatment period will receive rhPTH(1 -84) as a single 100 μg SC injection 
administered in the mid- thigh as either Formulation A or Formulation B depending on the 
randomized (1:1) treatment sequence as indicated in Table 6.a.
Blood samples for plasma PTH PK and serum calcium and albumin concentrations will be 
collected predose and for 24 hours following each rhPTH(1 -84) administration at the time points 
delineated in the Schedule of Study  Procedures (Section 3
).
There will be a drug washout of 96 (±1)hours between the administr ation of rhPTH(1- 84) in 
each period.
Table 6.a Study Scheme for Part I (Relative Bioavailability)
Treatment Sequence N Treatment Period 1Drug Washout
(Hours)Treatment Period 2
1 42 a 96 (±1) b
2 42 b 96 (±1) a
The planned dose levels of rhPTH(1 -84) to be evaluated are outlined in Table 6.c
Subjects will remain in the CRU until completion of the last p ostdose assessment on Day 2 of 
Treatment Period 2. If clinically  significant findings are observed upon discharge, subjects may
either be kept in the CRU for observation or return to the CRU for re -evaluation per 
Investigator’s discretion.
 
Safety  and tolerability  will be assessed by  [CONTACT_304514], 
laboratory  evaluations, phy sical examinations, 12 -lead ECGs, and vital signs.
All subjects who received a dose of study  drug(including subjects who terminate from the study  
early) will return to the CRU 16 (±2) days (return visit) and 32 (±2) days (follow -upvisit) after 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 27
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372664] study  visit .
Part II (Dose L inearity )
Part II (Dose L inearity )will be conducted as a randomized, four -sequence, four -period ,
crossover design. 
Subjects in each treatment period will receive rhPTH(1 -84) Formulation A as a single SC 
injection administered in the mid-thigh at a dose level depending on the randomized (1:1:1:1) 
treatment sequence as indicated in Table 6.b. If possible, the same location in the same thigh will 
be used for all treatment periods. If the same thigh cannot be used, the alternative mid- thigh may  
be used.
Blood samples for plasma PTH PK will be collected pre dose and for 24 hours following each 
rhPTH(1 -84) administration at the time points delineated in the Schedule of Study  Procedures 
(Section 3).
There will be a drug washout of 48 (±1)hours between the administration of rhPTH(1 -84) in 
each period.
Table 6.b Study Scheme for Part II (Dose Linearity)
Treatment 
SequenceN Treatment 
Period 1Drug 
Washout
(Hours)Treatment 
Period 2Drug 
Washout
(Hours)Treatment 
Period 3Drug 
Washout
(Hours)Treatment 
Period 4
1 3 c 48 (±1) d 48 (±1) e 48 (±1) f
2 3 d 48 (±1) f 48 (±1) c 48 (±1) e
3 3 e 48 (±1) c 48 (±1) f 48 (±1) d
4 3 f 48 (±1) e 48 (±1) d 48 (±1) c
The planned dose levels of rhPTH(1 -84) to be evaluated are outlined in Table 6.c
Subjects will remain in the CRU until completion of the last postdose assessment on Day 2 of 
Treatment Period 4.If clinically  significant findings are observed upon discharge, subjects may  
either be kept in the CRU for observation or return to the CRU for re -evaluation per 
Investigator’s discretion.
 
Safety  and tolerability  will be assessed by  [CONTACT_304514], 
laboratory  evaluations, phy sical examinations, 12 -lead ECGs, and vital signs.
All subjects who received a dose of study  drug (including subjects who terminate from the study  
early) will return to the CRU 16 (±2) days (return visit) and 32(±2)days (follow -upvisit) after 
the last study  drug administration for collection of blood  to determine 
if any  AEs have occurred since the last study  visit .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 28
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
The planned dose levels of rhPTH(1 - 84) to be evaluated are outlined in Table 6.c. 
Table 6.c Planned Dose Levels
Regim en Form ulation Dose Level Dose Form Route of Adm inistration
Part I (Relative Bioavailability)
a Form ulation A 
(test)100 µg rhPTH(1 -84) Lyophilized pow der to be 
reconstituted for SC dosingSC injection in mid -thigh
b Form ulation B 
(Reference)100 µg rhPTH(1 -84) Lyophilized pow der to be 
reconstituted for SC dosingSC injection in mid -thigh
Part II (Dose Linearity)
c Form ulation A 25 µg rhPTH(1 -84) Lyophilized pow der to be 
reconstituted for SC dosingSC injection in mid -thigh
d Form ulation A 50 µg rhPTH(1 -84) Lyophilized pow der to be 
reconstituted for SC dosingSC injection in mid -thigh
e Form ulation A 75 µg rhPTH(1 -84) Lyophilized pow der to be 
reconstituted for SC dosingSC injection in mid -thigh
f Form ulation A 200 µg rhPTH(1 -84) Lyophilized pow der to be 
reconstituted for SC dosingSC injection in mid -thigh
6.2 Dose Escalation
Not applicable.
6.3 Stoppi[INVESTIGATOR_304499].
6.4 Rationale for Study Design, Dose, and Endpoints
6.4.1 Rationale of Study Design 
The purpose of the study  is to assess the relative bioavailability of the new rhPTH(1 -84) 
formulation (Formulation A) compared with the currentl y used formulation (Formulation B) and 
the dose linearit y of the new formulation. Therelative bioavailability  of Formulation A with 
respect to Formulation B at the 100 µg dose strength (Part I [Relative Bioavailability ]) and the 
dose-exposure characteristics of Formulation A, evaluated over a dose range of 25 µg to 200 µg 
(Part II [Dose L inearity ]
),will enable extrapolation of the relative bioavailability of 
Formulation A to different dose levels.
By [CONTACT_304524] y subjects, the study will mainly focus on the difference in the exposure between 
the formulation s, and limit other factors on the dose -exposure response.
Subjects will be randomized to treatment sequences to minimize assignment bias. A crossover 
design is used to reduce the residual variability  as every  subject acts as their own control.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 29
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Based on previous clinical data, following SC administration to the thigh of 100 µg 
rhPTH(1 -84), PTH levels return to baseline within 16 -24 hours and s erum calcium levels return 
to baseline levels within 24 hours. Thus, the washout period between doses is considered 
sufficient to prevent carry over effects of the preceding treatment regimen.
 
 
 
 
 
 
 
 
6.4.2 Rationale for Dose 
The recommended therapeutic dose range for rhPTH(1- 84) (Natpara®) is 50 µg to 100 µg QD
(Natpara® [parath yroid hormone], 2020 ). In study  PBR 93 0811, a dose off up to 5.0 µg/kg, 
equivalent to an average dose of [ADDRESS_372665] ,was found safe and well 
tolerated. Thus, the dose of 100 µg was selected for the assessment of relative bioavailability  of 
the new formulation in Part I. 
A series of dosesranging from 25 µg to 200 µg rhPTH(1 -84) was selected for Part II (Dose 
Linearit y)to acquire a PK profile of the new formulation for a wide dose range. Based on the 
safet y profile of the drug, a dose of up to 350 µg is considered safe and well tolerated for a 70 kg 
adult, providing sufficient safet y margin in case of higher bioavailability  of the new formulation .
6.4.3
Rationale for Endpoints
[IP_ADDRESS] Pharmacokinetic Endpoints
The PK endpoints are standard for this type of relative bioavailability and dose linearity study .
[IP_ADDRESS] Safety Endpoints
The key  safet y endpoints are typi[INVESTIGATOR_304500] 1 studies and will be assessed through monitoring 
of AEs, vital signs, ECGs, laboratory  assessments, and phy sical examinations.
[IP_ADDRESS]
 
[IP_ADDRESS]
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 30
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372666] dosing. Tubes or containers will be 
identified with a barcode using an appropriate label.
No diseases/conditions, deox yribonucleic acid, or ribonucleic acid will be the focus of these 
analyses. Samples will not be submitted to a public database. The Sponsor and contract research 
organizations involved in the clinical conduct, bioanal ytical anal yses, and PK and statistical 
analysis of the data will have access to the samples and/or the data that resulted from the 
analysis, if performed. 
By [CONTACT_12568], subjects agree to the possible future analy sis of these samples. At any  time, 
the subjects can contact [CONTACT_304525] y are completed. An y additional 
research on these samples unspecified b y this protocol will require approval fr om the subjects.
6.4.5 Critical Procedures Based on Study Objectives: Timing of Procedures 
For this study , the critical component is the blood collection for plasma concentrations of PTH
and serum 
concentrations of calcium and albumin . The blood samples are to be collected as c lose 
to the scheduled times defined in this protocol as possible.
6.5 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
The dose and administration of the study  drugs to any  subject may  not be modified. If necessary , 
a subject may  be discontinued for the reasons described in Section 7.5.
6.6 Study Beginning and End/Completion
6.6.1 Definition of Beginning of the Study
The beginning of the study  will be defined as the beginning of the screening (ie, signing of the 
ICF) of the first subject.
6.6.[ADDRESS_372667] scheduled stud y procedure as outlined in th e 
Schedule of Study  Procedures (Section 3)
6.6.[ADDRESS_372668] to follow -up. 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 31
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
6.6.4 Definition of Study Discontinuation
The study  will be completed as planned unless 1 or more of the criteria indicated in Section 6.6.5
are satisfied that require temporary  suspension or earl y termination of the study .
6.6.5 Criteria for Premature Termination or Suspension of the Study
The study  will be completed as planned unless one or more of the following criteria are satisfied 
that require temporary  suspension or earl y termination of the study :
New information or other ev aluation regarding the safet y or efficacy of the study  drug 
indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for subjects participating in the study .
Significant violation of Good Clinical Pra ctice (GCP) compromises the ability  to achieve the 
primary  study  objectives or compromises subject safet y.
A finding (eg, PK, 
) from another nonclinical or clinical study  using the study  treatment 
results in the study  being stopped for a nonsafet y-relate d reason.
Data from drug(s) of the same class or methodology (ies) used in this study become available 
and result in the study  being stopped for a nonsafety -related reason.
The study  is stopped because of nonscientific and nonsafet y reasons, such as slow 
enrollment.
Unanticipated concerns of safet y to the stud y subjects arise from this clinical study or 
additional nonclinical or clinical studies with rhPTH(1- 84) or drug(s) of the same class.
6.6.6 Criteria for Premature Termination or Suspension of a Site
Not applicable.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 32
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
7. SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.[ADDRESS_372669] fulfill all of the following inclusion criteria to be eligible for participation in the 
study :
1.Health y, adult, male or female, [ADDRESS_372670] 20% of each sex in each study  part.
2.Continuous non- smoker who has not used nicotine containing products for at least [ADDRESS_372671] self -reporting.
3.BMI ≥18.5 and ≤30.0 kg/m2at screening.
4.Medically  healthy  with no clinically  significant medical history , phy sical examination, 
laboratory  profiles, vital signs or ECGs, as deemed by  [CONTACT_304526]:
Serum calcium, PTH, phosphate, and magnesium within laboratory  normal limits at 
screening and check -in.
Vitamin D ( 1,25(OH) 2D3) levels between lower limit of normal and up to 1.5x ULN.
Seated blood pressure is ≥89/49 mmHg and ≤139/89 mmHg at screening.
Seated 
pulse rate is ≥40 bpm and ≤99bpm at screening.
QTcF interval is ≤450 msec (males) or ≤470 msec (females) or ECG findings considered 
normal or not clinically  significant b y the Investigator or designee at screening.
Estimated creatinine clearance ≥80mL/minute at screening.
5.Agrees to compl y with any applicable contraceptive requirements of the protocol as detailed 
in Appendix D.
6.Understands the stud y procedures in the ICF, be able to voluntarily  provide written, signed, 
and dated informed consent, and be willing and able to comply  with the protocol.
7.[ADDRESS_372672] not be enrolled in the study  if they  meet any  of the following criteria:
1.Is mentally  or legall y incapacitated or has significant emotional problems at the time of the 
screening visit or expected during the conduct of the study in the opi[INVESTIGATOR_304501] I nvestigator 
or designee .
2.History  or presence of clinically  significant medical or psy chiatric condition or disease in the 
opi[INVESTIGATOR_25279].
3.History  of any  hematological, hepatic, respi[INVESTIGATOR_696], cardiovascular, renal, neurolo gical or 
psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the 
action, absorption, or disposition of the study  drug , or clinical or laboratory  assessments.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 33
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
4.Subjects who are at increased baseline risk for osteosarc oma such as subjects with Paget’s 
disease of bone or unexplained elevations of AL P, hereditary  disorders predisposing to 
osteosarcoma or a prior history  of external beam or implant radiation therapy  involving the 
skeleton.
5.History  of any  illness that, in t he opi[INVESTIGATOR_25279], might confound the 
results of the study  or poses an additional risk to the subject by  [CONTACT_304527] .
6.History  or presence of alcoholism or drug abuse , in the opi[INVESTIGATOR_304502], within the past 2years
prior to the first dosing.
7.Male subjects who consume more than 21 units of alcohol per week or 3 units per day . 
Female subjects who consume more than 14 units of alcohol per week or 2 units per day . 
(1alcohol unit=1 beer or 1 wine (5 oz/150 mL ) or 1 liquor (1.5 oz/40 mL) or 0.75 oz 
alcohol).
8.Positive urine drug or alcohol results at screening or check -in.
9.History  or presence of h ypersensitivity or idios yncratic reaction to the study drug or related 
compounds.
10.History  of abnorma lities of calcium homeostasis including hy perparathy roidism, 
hypoparathy roidism, hy perthy roidism, Cushing’s sy ndrome, h ypercalcemia, hy pocalcemia, 
osteoporosis, or an y other calcium disorder.
11.Female subjects with a positive pregnancy  test or who are lactat ing.
12. Positive results at screening for HIV, HBsAg, or HCV.
13. Has tattoo(s) or scarring at or near the site of injection or any  other condition which may  
interfere with injection site examination, in the opi[INVESTIGATOR_25279].
14. Routine consum ption of more than 2 units of caffeine per day  or subjects who experience 
caffeine withdrawal headaches. A unit of caffeine is contained in the following items: 
one 6 oz (180 mL ) cup of coffee, two 12 oz (360 mL ) cans of cola, one 12 oz cup of tea, 
three 1 oz (85 g) chocolate bars.
15. Prior screen failure, randomization, participation, or enrollment in this study or prior 
exposure to any  exogenous PTH, PTH fragments or analogs 3 months prior to dosing with 
rhPTH(1 -84).
16. Unable to refrain from or anticipates the use of any  medication or substance (including 
prescription or over -the-counter, vitamin supplements, natural or herbal supplements) as 
indicated in Section 7.3(Excluded Medication, Supplements, and Dietary  Products) for the 
prohibited time period .
17.Has been on a diet incompatible with the study  diet or had any  substantial changes in eating 
habits, i n the opi[INVESTIGATOR_25279], within the [ADDRESS_372673] dosing.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 34
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372674] blood collection 
or dosing, whichever is later, in the previous study to D ay1 of Treatment Period 1 of the 
current stud y.
7.3 Excluded Medications, Supplements, and Dietary Products 
Concomitant medications will be prohibited as follows:
Any drug, including prescription and or over -the-counter, vitamin supplements, natural or 
herba l supplements within [ADDRESS_372675] dosing and throughout the study . 
Medication listed as part of acceptable birth control methods will be allowed (refer to 
Appendix D). After randomization, acetaminophen (up to 2 g per 24 hours) , calcium 
gluconate and other medication for the treatment of AEs, may be administered at the 
discretion of the Investigator or de signee.
Thiazide diuretics within [ADDRESS_372676] dosing and throughout the study .
Loop diuretics, lithium, antacids, sy stemic corticosteroids within [ADDRESS_372677] 
dosing and throughout the study  (medical judgment is required by  [CONTACT_29256]). 
Primarily ,high doses of sy stemic corticosteroids [ eg, prednisone] and/or stable doses of 
hydrocortisone [ eg, as treatment for Addison’s disease] may  be acceptable at the 
Investigator’s or designee’s discretion.
Calcitonin, cinacalcet hydro chloride, treatment with rhPTH(1- 84) or N -terminal PTH or 
PTH -related peptide fragments or analogs within [ADDRESS_372678] dosing and 
throughout the stud y
.
For females: changes in hormone replacement therap y within [ADDRESS_372679] 
dosing and throughout the study  are excluded. Stable ( ≥3 months) hormone replacement 
therap
y is acceptable.
Fluoride tablets, oral bisphosphonates, methotrexate, growth hormone, digoxin, raloxifene or 
similar selective estrogen receptor modulators within [ADDRESS_372680] dosing and 
throughout the stud y.
Intravenous bisphosphonates within [ADDRESS_372681] may continue participation in the study .
All medications taken b y subjects during the course of the stud y will be recorded.
Use of excluded agents (prescription or non -prescription) or dietary  products is outlined in
Table 7.a.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 35
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372682] Dosing 
(Days -21 to predose [Day 1 of 
Treatm entPeriod 1 ])After First Dosing (Day 1 of 
Treatm ent Period 1 ) to Follow -Up
Alcohol Prohibited from 48hours prior to first 
dosingProhibited from first dosing until the end
of PK collection in the last study period .
Xanthine and/or caffeine Prohibited from [ADDRESS_372683] dosing throughout 
the study .
Nicotine -and tobacco -
containing and/or 
cannabis productsProhibited from [ADDRESS_372684] study period.
(a) small amounts of caffeine derived from normal foodstuffs eg , 250 mL/8 oz/1 cup decaffeinated coffee or other 
decaffeinated beverage, per day, with the exception of espresso; 45g/1.[ADDRESS_372685] from all 
food and drink except water between meals and snacks.
Each meal and/or snack served at the CRU will be standardized ,will be similar in caloric content
and composition, and will be taken at approximately  the same time in each period.
7.4.[ADDRESS_372686] sports at any  time from screening until completion of the 
study .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 36
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372687]
1.Pretreatment event (PTE) or AE: The subject has experienced a PTE or AE that requires 
early termination 
because continued participation imposes an unacceptable risk to the 
subject’s health or the subject is unwilling to continue because of the PTE or AE.
Liver Function Test (LFT) Abnormalities
Study  drug should be discontinued immediately  with appropriate clinical follow -up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
normal/ baseline status, see Section [IP_ADDRESS] ), if the following circumstances occur at any  
time during stud y drug treatment:
- A lanine aminotransferase ( ALT) or aspartate aminotransferase ( AST ) >5x ULN, or
-ALT or AST >3x ULN in conjunction with elevated bilirubin >2x UL N or 
international normalized ratio (INR)>1.5xULN, or
-ALT or AST >3x ULN with appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%), or
-ALT >[ADDRESS_372688] 24 to 48 hours apart.
2.Significant protoc ol deviation: The discovery  post -randomization that the subject failed to 
meet protocol entry  criteria or did not adhere to protocol requirements, and continued 
participation poses an unacceptable risk to the subject’s health.
3.Lost to follow -up: Attempts t o contact [CONTACT_57509]. Attempts to contact [CONTACT_304528]’s source documents.
4.Voluntary  withdrawal: The subject wishes to withdraw from the study . The reason for 
withdrawal, if provided, should be recorded i n the case report form (CRF).
Note: All attempts should be made to determine the underl ying reason for the withdrawal 
and, where possible, the primary  underl ying reason should be recorded (ie, withdrawal due to 
an AE should not be recorded in the “voluntar y withdrawal” category ). If a subject chooses 
to withdraw from stud y participation due to personal concerns related to the COVID -19 
pandemic (other than a COVID -19-related AE), this should be specified as the reason for 
subject withdrawal in the CRF.
5.Study termination: The Sponsor, Institutional Review Board (IRB)/Independent Ethics 
Committee (IEC), or regulatory  agency  terminates the study .
6.Pregnancy : as described in Appendix D.
7.Subjects may  be withdrawn from the study  by [CONTACT_941] I nvestigator or designee for the following 
reasons:
-Positive drug or alcohol screen results.
-Difficulties in blood collection
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 37
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372689]’s study  participation at any  time during the study  
when the subject meets the study  termination criteria described in Section 7.5. In addition, a 
subject may  discontinue his or her participation without giving a reason at any  time during the 
study . Should a subject’s participation be discontinued, the primary  criterion for termination 
must be recorded b y the Investigator. In addition, efforts should be made to perform all 
procedures scheduled for the end -of
-treatments or earl y termination as described in Section 3.
7.[ADDRESS_372690] Replacement
Replacement of discontinued or withdrawn subjects due to any  reason will be assessed on a case 
by [CONTACT_413] b y the Sponsor and Investigator to ensure a minimum of 76PK-evaluable subj ects 
complete Part I (Relative Bioavailability) of the study ,and a minimum of 
8 PK -evaluable 
subjects complete Part II (Dose Linearity) of the study .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 38
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372691] Name: [CONTACT_304550][1-
84]
Strengths: 25 µg, 50 µg, 75 µg, 100 µg 
The 200 µg dose will be achieved using two consecutive injections of the 100 µg
Dosage Form/Formulation: Ly ophilized powder to be reconstituted for SC dosing.
Dosing regimen: Single dose
Route of Administration: SC injection in mid -thigh
Investigational product will be supplied as: multiple -dose, dual -chamber glass cartridges 
containing a sterile l yophilized powder and a diluent for reconstitution at a dose of either [ADDRESS_372692].
8.1.1 Clinical Study Drug Labeling
Study  drug containers w ill be affixed with a clinical label in accordance with local regulatory  
requirements.
8.1.2 Clinical Study Drug Inventory and Storage
The same lot number will be used throughout the study. The lot numbers and expi[INVESTIGATOR_1659] 
(where available) of the study  drug s supplied will be recorded in the final report. Study  drugs 
will be stored according to the product labels provided with the product.
Records will be made of the receipt, preparation, dispensing, and final disposition of the study  
drugs supplied.
8.1.3 Clinical Study Drug Blinding
This is an open -label study . 
8.1.4 Randomization Code Creation and Storage 
A computerized randomization scheme will be created b y a Celerion statistician according the 
treatment sequences indicated in Table 6.a(Part I [Relative Bioavailability ]) and Table 6.b
(Part II [Dose Linearity]
).
8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
Not applicable.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 39
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
8.1.6 Accountability and Destruction of Sponsor
-Supplied Drugs
Records will be made of the receipt and dispensing of the stud y drugs supplied. At the 
conclusion of the study , any  unused rhPTH(1 -84) will be retained b y Celerion, returned to the 
Sponsor or designee , or destroy ed, as per Sponsor instructions. If no supplies remain, this fact 
will be documented in the pharmacy  product accountability  records.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 40
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
9. STUDY PROCEDURES
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
The purpose of the study , the procedures to be carried out and the potential hazards will be 
described to the subjects in non- technical terms. Subjects will be required to read, sign, and date 
an ICF summarizing the di scussion prior to screening, and will be assured that they  may  
withdraw from the stud y at an y time without jeopardizing their medical care.
Subjects will be given a copy  of their signed ICF .
[IP_ADDRESS] Assignment of Screening and Randomization Numbers 
Each subject w ill be assigned a unique identification number upon screening. Subjects who 
complete the study  screening assessments and meet all the eligibility  criteria will be assigned a 
unique identification number at the time of dosing, different from the screening n umber.
Subjects in each stud y part will be randomized to treatment sequence according to Table 6.a
(Part I [Relative Bioavailability ]) and Table 6.b(Part II [Dose Linearity] ).
If replacement subjects are used , the replacement subject number will be 100 more than the 
original (eg, Subject No. [ADDRESS_372693] No. 1).
[IP_ADDRESS] Study Drug Assignment
All subjects will receive the treatments as detailed in Section
 9.2.6.
9.1.2 Inclusion and Exclusion 
Please r efer to Section 
7.1and Section 7.2.
9.1.3 Medical History/ Demography
Medical history and demographic data, including name, sex, age, race, ethnicity , and history  of 
tobacco use will be recorded.
9.1.4 Concomitant Medications
Concomitant m edications will be prohibited as listed in Section 7.3
. All medications taken b y 
subjects during the course of the stud y will be recorded.
9.2 Clinical Procedures and Assessments
The Schedule of Stud y Procedures ( Section 3) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below. Additional 
evaluations/testing may  be deemed necessary  by [CONTACT_25308]/or the Sponsor 
for reasons related to subject sa fety.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 41
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372694] time point as possible. All other procedures shou ld be completed as close to the 
prescribed/scheduled time as possible, but can be performed prior to or after the 
prescribed/scheduled time.  
Any nonscheduled procedures required for urgent evaluation of safet y concerns take precedence 
over all routine scheduled procedures.
9.2.1 Full Physical Exam
Full phy sical examination swill be performed as outlined in the Schedule of Study  Procedures 
(Section 3). Symptom -driven phy sical examinations may  be performed at other times, if deemed 
necessary  by [CONTACT_18370].
9.2.2 Height and Weight
Body height (cm) and weight (kg) will be reported as outlined in the Schedule of Study 
Procedures (Section 3).
9.2.3 BMI
BMI (kg/m2)will be calculated based on the height and weight measured at screening.
9.2.4 Vital Signs
Single measurements of temperature, respi[INVESTIGATOR_2842], blood pressure ,andpulse rate will be 
measured as outlined in the Schedule of Stud y Procedures (Section 3). Additional vital signs may  
be taken at any  other times, if deemed necessary .
Blood pressure and 
pulse rate measurements will be performed with subjects in a seated position, 
except when they  are supi[INVESTIGATOR_1662] -reclined because of study  procedures and/or AEs 
(eg,nausea, dizziness) or if d eemed necessary  by [CONTACT_304529].
Blood pressure and pulse rate will be measured within approximately  30 minutes prior to Day 1 
dosing of each period for the predose time point. When scheduled postdose, vital signs will be 
performed within approximately  15minutes of the scheduled time point. 
9.2.5 12- Lead ECG
Single 12
-lead ECGs will be performed as outlined in the Sche dule of Study  Procedures 
(Section 3). Addi tional ECGs may  be taken at any other times, if deemed necessary  by [CONTACT_304530].
ECGs will be performed with subjects in a supi[INVESTIGATOR_2547]. All ECG tracings will be reviewed b y 
theInvestigator or designee.
ECGs will be measured within approximately 30 minutes prior to Day 1 dosing of each period 
for the predose time point. When scheduled pos tdose, ECGs will be performed within 
approximately  20minutes of the scheduled time point.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 42
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
9.2.6 Injection Site Evaluation
In monitoring AEs, special attention will be paid to potential injection site reactions ( ie, local 
tolerability ). Any abnormal findings wi ll be reported as AEs. 
9.2.7 Study Drug Administration
rhPTH(1 -84) formulation swill be provided as described in Section 8.1.
Treatments will be administered as described in Table 6.c.
The pharmacy  at the CRU will provide each dose in individual injector pen with a sterile, 
disposable pen needle. Each individual injector pen will be used for onl y one subject. To 
administer a [ADDRESS_372695] be administered as soon as 
possible, 
within no more than 5 minutes of each othe
r, one in each thigh.
In Part I (Relative Bioavailability ), the same location in the same thigh will be used for both 
treatment periods, if possible. I n Part II (Dose Linearit y), alternate thighs may  be used in 
successive treatment periods.
All injections will be administered by  a qualified designee, eg , a nurse. In the case of an 
incomplete dosing ( eg, droplet(s) of study  medication on the surface of the skin) as deemed b y 
the Investigator and Sponsor or Sponsor’s designee, the subject may  be withdrawn.
Additional information regarding drug preparation and administration may be provided in a 
separate pharmacy  manual.
The exact clock time of dosing will be recorded.
For Treatments a and b 
(Part I [Relative Bioavailability ]), and Treatments c, d, and e (Part II 
[Dose L inearity ]), Hour 0 will be define as the time of injection. For Treatment 
f(Part II [Dose 
Linearit y]), Hour 0 will be define as the time of the second injection.
In each stud y part, treatment administration in consecutive treatment period 
(ie,Treatment Period 2 in Part I  and Treatment Periods 2, 3, and 4 in Part II) will be 
administered time of day (±1hour) as treatment administration in Treatment Period 1.
9.2.8 AE Monitoring
Subjects will be monitored throughout the study  for adverse reaction s to the study  drugs and/or 
procedures as described in Section 10.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 43
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
9.2.9 Laboratory Procedures and Assessments
All tests listed below will be performed as outlined in the Schedule of Study Procedures 
(Section 3). In addition, laboratory  safet y tests may be performed at various unscheduled time 
points, if deemed necessary  by [CONTACT_18370].
[IP_ADDRESS] Clinic al Laboratory Tests
Hematology
Hematology  will consist of the following tests:
Hem oglobin Red blood cell count
Hem atocrit Platelet count
Total and differential leukocyte count
Chemistry  
Serum chemistry  tests will be performed after at least an [ADDRESS_372696]; however, in case of 
dropouts or rechecks, subjects may  not have fasted for [ADDRESS_372697] chemistry  panel:
Amylase Albumin
Lipase Potassium
Blood Urea Nitrogen Chloride
Bilirubin (total and direct) Glucose 
Alkaline phosphatase (ALP) Creatinine *
Aspartate aminotransferase (AST) Magnesium
Alanine aminotransferase (ALT) Sodium
Calcium Phosphate
* At screening, creatinine clearance will be calculated using the Cockcroft -Gault formula.
Urinaly sis
Urinaly sis will consist of the following tests:
pH Bilirubin
Specific gravity Blood *
Protein * Nitrite *
Glucose Urobilinogen
Ketones Leukocyte esterase *
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red 
blood cells, white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be performed.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 44
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372698] Urine drug screen
-Opi[INVESTIGATOR_858] (includes morphine, heroi n 
(diacetylmorphine), codeine, 6 -acetylmorphine, 
dihydrocodeine, hydrocodone, thebaine, and, 
hydromorphone)
-Amphetamines
-Barbiturates
-Benzodiazepi[INVESTIGATOR_1651]
-Cocaine
-CannabinoidsHBsAg
HCV (if antibody positive, confirm RNA negative)
Urine alcohol screen
Serum pregnancy test (for females only)
FSH (for females only)
Urine cotinine
Vitamin D
PTH
COVID -19 testing (performed according to CRU 
standard procedures, provided in a separate 
document[s])Thyroid stimulating hormone (TSH)
Free thyroxine (T4)
9.3 Pharmacokinetics ,
Instructions for sample collection, processing, and shippi[INVESTIGATOR_22016] a separate 
laboratory  manual .
Primary  specimen collection parameters are provided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrim ary 
SpecimenPrim ary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Plasma sample for PK Blood Plasma Plasma sample for PK analysis Mandatory
9.3.1 PK Measurements 
Samples from all subjects will be assay ed even if the subjects do not complete the study . 
Samples for determination of plasma PTH , will be anal yzed using validated bioanaly tical 
methods.
Pharmacokinetic parameters of PTH will be calculated from the individual concentration -time 
profiles from all evaluable subjects using noncompartmental anal ysis methods. Actual sampling 
times, rather than scheduled sampling times, will be used in all computations involving sampling 
times. 
[IP_ADDRESS] Plasma for PK Measurements
The following PK parameters will be calculated from unadjusted and baseline- adjusted plasma 
concentrations of PTH , unless otherwise specified:
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 45
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372699]: The area under the concentration
-time curve, from time [ADDRESS_372700] 
quantifiable concentration, as calculated by  [CONTACT_1690] -log trapezoidal 
method.
AUC ∞: The area under the concentration- time curve, from time 0 extrapolated to 
infinity . AUC is calculated as AUC lastplus the ratio of the last 
measurable blood concentration to the eli mination rate constant.
AUC extrap% : The area under the curve from the last quantifiable concentration to 
infinity , expressed as a percentage of AUC 
Cmax: Maximum observed concentration.
tlast: Time of the last measurable concentration.
tmax: Time to r each C max. If the maximum value occurs at more than one time 
point, t maxis defined as the first time point with this value.
t½z: Terminal disposition phase half -life will be calculated as 0.693/λ z, where
λzis the apparent first order terminal disposition phase rate constant 
calculated from a semilog plot of the plasma concentration versus time 
curve. The parameter will be calculated b y linear least -squares-regression 
analysis using the maximum number of poi nts in the terminal log- linear 
phase (eg, three or more non- zero plasma concentrations).
No value for AUC ∞, AUC extrap% ,or t½ zwill be reported for cases that do not exhibit a terminal 
log-linear phase in the concentration versus time profile.
No PK param eters will be calculated for subjects with detectable concentrations at 2 or fewer 
consecutive time points. 
Individual and mean plasma concentration -curves (both linear and log -linear) will be included in 
the final report. 
Additional PK parameters may  beestimated as appropriate.
9.3.2
 
 
 
 
 
[IP_ADDRESS]
 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 46
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
 
 
 
 
 
9.3.3  
 
 
9.3.4
Biomarker Measurements 
Not applicable.
9.3.5 PGx Measurements 
Not applicable.
9.3.6 Confinement
Subjects will be housed on Day  -1of Treatment Period 1 , at the time indicated by  [CONTACT_47365], until 
after the 24-hour blood draw and/or stud y procedures in Treatment Period 2 (Part I [Relative 
Bioavailability ]) or Treatment Period 4 (Part II [Dose Linearit y]). Subjects may  be admitted 
earlier for COVID -[ADDRESS_372701] may be required to remain at the CRU for longer at the discretion of the 
Investigator or designee.
All subjects who received a dose of study  drug (including subjects who terminate from the study  
early) will return to the CRU 1
6(±2) days (return visit) and 32(±2)days (follow - upvisit) after 
the last study  drug administration for collection of blood to determine 
if any  AEs have occurred since the last study  visit .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 47
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372702] who has 
signed informed consent to participate in a stud y; it does not necessarily  have to ha ve a causal 
relationship with the treatment.
An AE can therefore be any  unfavorable and unintended sign (eg, a clinically  significant 
abnormal laboratory  finding), s ymptom, or disease temporall y associated with the use of a drug, 
whether or not it is consi dered related to the drug.
An untoward finding generall y ma y:
Indicate a new diagnosis or unexpected worsening of a preexisting condition. (Intermittent 
events for pre -existing conditions or underly ing disease should not be considered AEs.)
Necessitate 
therapeutic intervention.
Require an invasive diagnostic procedure.
Require discontinuation or a change in dose of study  medication or a concomitant 
medication.
Be considered unfavorable by  [CONTACT_304531].
Diagnoses versus signs and sy mptoms:
Each event should be recorded to represent a single diagnosis. Accompan ying signs 
(including abnormal laboratory  values or ECG findings) or s ymptoms should NOT be 
recorded as additional AEs. If a diagnosis is unknown, sign(s) or s ymptom(s) should be 
recorded appropriatel y as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG parameters may be considered AEs if they  are judged to 
be clinically  significant (ie, if some action or intervention is required or if the investigator
judges the change to be bey ond the range of normal phy siologic fluctuation). A laboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. 
In addition, repeated or additional noninvasive testing for verification , evaluation or 
monitoring of an abnormality  is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology  for which there is 
an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis onl y should be 
reported appropriately  as an AE.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 48
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Pre-existing conditions:
A pre -
existing condition (present at the time of signing of informed consent) is considered a 
concurrent medical history  condition and should NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) should NOT be recorded as an AE unless 
related to a stud y procedure. However, if the subject experiences a worsening or 
complication of such a concurrent medical history  condition, the worsening or complication 
should be recorded appropriately  as an AE (worsening or complication occurs after informed 
consent is signed). Investigators should ensure that the event term recorded captures the 
change in the condition (eg, “worsening of…”).
If a subject has a pre -existin g epi[INVESTIGATOR_174343] (eg, asthma, epi[INVESTIGATOR_30989] y), an y occurrence of an 
epi[INVESTIGATOR_304503], serious, or 
severe in nature, that is, investigators should ensure that the AE term recorded captures the 
chang e from Baseline in the condition (eg , “worsening of…”).
If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condition should only  be captured as an AE if occurring to a greater extent 
to that which w ould be expected. Again, investigators should ensure that the AE term 
recorded captures the change in the condition (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complication of an AE after the first administration 
of study medication or after an y change in stud y medication, the worsening or complication 
should be recorded as a new AE. Investigators should ensure that the AE term recorded 
captures the change in the condition (eg, “worsening of…”).
Changes in severit y of AEs:
If the subject experiences a change in the severity  of an AE that is not associated with a 
change in stud y medication, the event should be captured once with the maximum severity 
recorded.
Preplanned surgeries or procedures:
Preplanned procedures (sur geries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
informed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -existing condition, the worsening 
of the conditi on should be captured appropriatel y as an AE. Complications resulting from 
any planned surgery  should be reported as AEs.
Elective surgeries or procedures:
Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as AEs but should be documented in the subject’s source documents. 
Complications resulting from an elective surgery  should be reported as AEs.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 49
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or b y a study subject, at a dose above that which is assigned to that individual subject 
according to the stud y protocol. I t is up to the investigator or the reporting phy sician to 
decide whether a dose is to be considered an overd ose, in consultation with the Sponsor.
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the (e)CRF, in order to capture this important safet y information consistently  in the 
database. AEs associated with an o verdose will be documented on AE CRF(s) according to 
Section 10.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Section 10.2.8 .
In the event of drug overdose, the subject should be treated s ymptomatically .
10.1.[ADDRESS_372703] medical occurrence that at an y dose:
1. Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” r efers to an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event that hy pothetically  might have caused 
death if it were more severe.
3. Requires inpatient HOSPI[INVESTIGATOR_304504].
4.Results in persistent or significant DISABILITY/INCAPACI TY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDI CAL  EVENT that satisfies an y of the following:
May require intervention to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Includes an y event or s ynonym described in the [COMPANY_005] Medically  Significant AE L ist 
(Table 10.a).
Considered an IMPORTANT MEDICAL EVENT in the opi[INVESTIGATOR_304505].
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 50
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372704]
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_4072] / ventricular fibrillation / 
ventricular tachycardiaAnaphylactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent 
by a medicinal productToxic epi[INVESTIGATOR_194]/
Stevens -Johnson syndrom e
COVID -19 pneumoniaNeuroleptic malignant syndrome / malignant 
hyperthermia
COVID -19-related disease Spontaneous abortion / stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner (see Section 10.1 and Section 10.1.1).
10.1.[ADDRESS_372705] AEs will include hyper-and hypocalcemia as determined by  [CONTACT_304532] .
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories of severit y/intensity  are:
Mild: An AEthat is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: An AEthat is usually  alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily  living, 
causing discomfort but poses no significant or permanent risk of harm to the 
research participant.
Severe: An AEthat interrupts usual activities of daily  living, or significantly  affects 
clinical status, or may  require intensive therapeutic intervention.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 51
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
10.2.2 Assigning Causality of AEs
The relationship of each AE to study  medication(s) will be assessed using the following 
categories:
Related: An AE that follows a reasonable temporal sequence from administration of a 
drug (including the course after withdrawal of the drug), or for which a 
causal relationship is at least a reasonable possibility , 
ie, the relationship 
cannot be ruled out , although factors other than the drug, such as underly ing 
diseases, complications, concomitant drugs and concurrent treatments, may 
also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from 
administration of a drug and/or tha t can reasonably  be explained by  [CONTACT_209790], such as underl ying diseases, complications, concomitant 
medications, and concurrent treatments.
10.2.[ADDRESS_372706] signs/s ymptoms were noted by  [CONTACT_3184]/or 
investigator.
10.2.[ADDRESS_372707] died.
10.2.5 Pattern of Adverse Event (Frequency) 
Epi[INVESTIGATOR_11742] (eg, headache) or those which occur repeatedl y over a period of consecutive days 
are intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn – a study medication is stopped due to the particular AE.
Dose not changed –the particular AE did not require stoppi[INVESTIGATOR_007] a study  medication.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a stud y medication was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the subject died, dosing with study  medication had not y et 
started or dosing with study  medication was already  stopped before the onset of the AE.
Dose reduced – the dose was reduced due to the particular AE.
Dose increased – the dose was increased due to the particular AE.
Drug interrupted –the dose was interrupted due to the particular AE.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 52
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
10.2.7 Outcome 
Recovered/resolved –subject returned to first assessment status with respect to the AE.
Recovering/resolving –the intensity  is lowered by  [CONTACT_1734]: the diagnosis has or 
signs/sy mptoms have almost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the subject died from a cause other 
than the particular AE with the condition remaining “recovering/resolving. ”
Not recovered/not resolved –there is no change in the diagnosis, signs or sy mptoms; the 
intensity  of the diagnosis, signs/sy mptoms or laboratory  value on the last day  of the observed 
study  period has become worse than when it started; is an irreversible congenital anomal y; 
the subject died from another cause with the particular AE state remaining “Not 
recovered/not resolved.”
Recovered/ Resolved with sequelae –the subject recovered from an acute AE but was left 
with permanent/significant impairment (eg, recovered from a cardiovascular accident but 
with some persisting paresis).
Fatal –an AE that is considered as the cause of death.
Unknown –
the course of the AE cannot be followed up due to hospi[INVESTIGATOR_47350]’s participation in the study .
10.2.[ADDRESS_372708] AEs, and Abnormal 
LFTs
[IP_ADDRESS] Collection Period
Collection of AEs (ie, AEs, SAEs, Special Interest AEs, and Abnormal LFTs) will commence at 
the time the subject signs the informe d consent. Routine collection of AEs will continue until the 
follow -up visit 32 ( ± 2) day s after the last dose of study  drug . For subjects who discontinue prior 
to the administration of study  medication, AEs will be followed until the subject discontinues 
study participation. 
[IP_ADDRESS] Reporting AEs
At each stud y visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may  be asked. 
Subjects may  report AEs occurring at any other time during the stud y. Subjects experiencing an 
SAE prior to the first exposure to investigational product must be monitored until the sy mptoms 
subside and an y clinically relevant changes in laboratory values have returned to Baseline or 
there i s a satisfactory  explanation for the change. Nonserious AEs that begin prior to the first 
exposure to investigational product, related or unrelated to the study procedure, need not be 
followed-up for the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study  
medication or not, must be monitored until the symptoms subside and any  clinically  relevant 
changes in laboratory  values have returned to Baseline or until there is a satisfactory  explanation 
forthe changes observed. All AEs will be documented in the AE page of the CRF, whether or 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 53
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
not the investigator concludes that the event is related to the drug treatment. The following 
information will be documented for each event:
Event term.
Start and end d ate and time.
Pattern of AE (frequency).
Severity /Intensity .
Causality  (Investigator’s opi[INVESTIGATOR_304506][s]).
Action taken with study  drug.
Outcome of event.
Seriousness.
[IP_ADDRESS] Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A [COMPANY_005] SAE form must be completed, in English and signed by  [CONTACT_43054] y 
or within [ADDRESS_372709] onset or notification of the event. The information should be 
completed as full y as possible but contain, at a minimum:
A short description of the event and the reason why the event is categorized as serious.
Subject identification number.
Investigator’s name.
Name [CONTACT_304551](s).
Causality  assessment.
The SAE form should be transmitted within [ADDRESS_372710] will follow 
the same procedure for SAEs occurring on treatment.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 54
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372711] report becomes available at a later date, the 
investigator should complete a follow -up 
SAE form or provide other written documentation and 
faxor email it immediately  within 24 hours of receipt. Copi[INVESTIGATOR_304507] (eg, ECGs, laboratory  tests, discharge summary , postmortem results) should be 
sent to the addressee, if requested.
All SAEs should be followed up until resolution or permanent outcome of the event. The 
timelines and procedure for follow
-up reports are the same as those for the initial report.
[IP_ADDRESS] Reporting Special Interest AEs 
When a special interest AE occurs through the AE collection period it should be reported within 
[ADDRESS_372712] listed in 
Section 14.1.1 .
[IP_ADDRESS] Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3 ×ULN on [ADDRESS_372713] >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternative etiology  has not been identified, the event should be recorded as an SAE and reported 
as per Section [IP_ADDRESS]. The investigator must contact [CONTACT_137984] r for discussion of the 
relevant subject details and possible alternative etiologies, such as acute viral hepatitis A or B or 
other acute liver disease. Follow -up laboratory  tests as described in Section [IP_ADDRESS] must also be 
performed. In addition, an LFT Increases CRF must be completed and transmitted with the 
[COMPANY_005] SAE form (as per Section 10.2.9). 
10.2.9 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) and an y other applicable SAEs to regulatory  authorities, investigators and IRBs or 
IECs, as applicable, in accordance with national regulations in the countries where the stud y is 
conducted. Relative to the first awareness of the event by /or further provision to the Sp onsor or 
Sponsor’s designee, S[LOCATION_003]Rs will be submitted within [ADDRESS_372714] a copy  of all 
expedited reports to his or her IRB or IEC in accordance with national regulations.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 55
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
11. STATISTICAL METHODS
11.1 Statistical and Analytical Plans
Detailed methodology  for summary  and statistical 
analyses of the data collected in this study  will 
be documented in a statistical anal ysis plan (SAP). The SAP will be prepared by  [CONTACT_304533]. This document may modify the plans outlined in the protocol; 
however, an y major mod ifications of the primary  endpoints definition and/or its analy sis will 
also be reflected in a protocol amendment. Additional statistical analy ses other than those 
described in this section may  be performed if deemed appropriate.
11.1.1 Analysis Sets
[IP_ADDRESS] PK Set
All subjects who have at least one measurable predose (baseline) and one postdose concentration 
of PTH will be included in the statistical analy ses.
[IP_ADDRESS] Safety Set
All subjects who received at least one dose of the study  drug will be included in the safet y 
evaluations.
[IP_ADDRESS]
 
[IP_ADDRESS]
 
11.1.2 Analysis of Demography and Other Baseline Characteristics
Continuous demographic data (ie, age, weight, height, and BMI) will be listed and summarized 
using appropriate summary statistics. Categorical demographic data (ie, gender, race, and 
ethnicity ) will also be listed and tabulated.
11.1.[ADDRESS_372715] as described in Section [IP_ADDRESS] . 
PK parameters for each su bject will be listed and su mmarized by  [CONTACT_33344].
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 56
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
[IP_ADDRESS] Relative Bioavailability (Part I [Relative Bioavailability] )
Analy sis of Variance
A linear mixed -effects model will be used for the anal ysis on the ln- transformed AUC last, AUC ,
and C maxfor PT H. The model will include sequence, treatment, and period as fixed effects and 
subject nested within sequence as a random effect . The anal ysis will include calculation of L SMs 
as well as the difference between treatment regimen L SMs.
Ratios and Confidence Intervals
GMR and 90% CI, consistent with the two one- sided test (Schuirmann, 1987) , will be calculated 
using the exponentiation of the difference between tre atment regimen LSMs from the anal yses 
on the ln- transformed AUC , AUC last,and C maxfor PTH. These ratios will be expressed as a 
percentage relative to the appropriate reference formulation or treatment regimen. 
[IP_ADDRESS] Dose Linearity (Part II [Dose Linearity] )
Apparent dose linearit
y of PK parameters (selected baseline -adjusted AUC and C maxparameters) 
will be assessed graphically .
[IP_ADDRESS] Non-Parametric Analysis
The PK parameter t maxwill be analy zed using an appropriate nonparametric anal ysis; t maxwill 
not be ln- transformed. 
11.1.[ADDRESS_372716].
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 57
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Statistical analy sis of safety  data will be based on the safet y anal ysis data set. 
TEAEs will be tabulated. The remaining quantitative safet y data as well as the difference to 
baseline, when appropriate, will be summarized using the appropriate descriptiv e statistics.
[IP_ADDRESS] AEs
AEs will be coded using the most current version of Medical Dictionary  for Regulatory  
Activities (MedDRA®) available at Celerion and summarized by  [CONTACT_304534]. A by-
subject AE data listing 
including verbatim term, coded term, treatment, severity , and relationship to treatment will be 
provided.
[IP_ADDRESS] C linical Laboratory Evaluation
Clinical laboratory results will be summarized by  [CONTACT_25321] a 
shift table describing out of normal range shifts will be provided.
[IP_ADDRESS] Vital Signs
Vital signs assessments will be summarized by  [CONTACT_25322].
[IP_ADDRESS] Other Safety Parameters
Physical examination findings will be presented in the d ata listings.
ECGs will be summarized by  [CONTACT_25322].
Medical history , and concurrent conditions will be coded using the MedDRA®and concomitant 
medications will be coded using the World Health Organization (WHO) drug diction ary and will 
be listed by  [CONTACT_1130].
11.2 Interim Analysis and Criteria for Early Termination
In Part I (Relative Bioavailability ), an interim PK anal ysis will be conducted following 
completion of Treatment Period [ADDRESS_372717] will be made as a result of interim 
analysis.
11.3 Determination of Sample Size
Part I (Relative Bioavailability ):
The sample size of 76 subjects was calculated to achieve 90% CI around the geometric mean 
ratio of the test and reference formulations within the limits of 0.[ADDRESS_372718] to reference ratio was as sumed to be 0.93, and 90% target power was used for the 
sample size determination. The I SCV was assumed to be 
32.2%, the upper end of the two -sided 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 58
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
50% confidence limit of the I SCV for 
Cmaxestimated in study  SHP634-103 (the I SCV observed 
in study  SHP634-103 was higher for C maxthan for AUC) . Part I (Relative Bioavailability )will 
enroll 84 subjects to allow for up to eight dropouts.
Part II (Dose L inearity ):
The sample size for Part II (Dose Linearit y)is not based on any  statistical considerations but is 
considered sufficient for dose linearit y evaluation.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 59
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
12. QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study -Site Monitoring Visits
Monitoring visits to the study  site will be made periodically  during the study  toensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the CRFs. Source documents are defined as original documents, data, and records. 
The investigator and study  site guarantee access to source documents by  [CONTACT_152486] (CRO) and b y the I RB or IEC.
All aspects of the stud y and its documentation will be subject to review b y the Sponsor or the 
Sponsor’s designee (as long as blinding is not jeopardized), including but not li mited to the 
Investigator’s Binder, study drug, subject medical records, informed consen t documentation, and 
review of CRFs and associated source documents. I t is important that the investigator and other 
study  personnel are available during the monitoring visits and that sufficient time is devoted to 
the process.
12.[ADDRESS_372719] to study subjects. Should other unexpected circumstances arise th at will 
require deviation from protocol
-specified procedures, the investigator should consult with the 
sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action. 
There will be no exemptions (a prospectively  approved de viation) from the inclusion or 
exclusion criteria.
For COVID -19-related protocol deviations, the specific protocol deviation, the reason for the 
deviation, and the relationship to COVI D-[ADDRESS_372720]
es are collected, 
where the medication is stored and prepared, and any  other facility  used during the stud y. In 
addition, there is the possibility  that this study  may be inspected b y regulatory  agencies, 
including those of foreign governments (eg, the FDA, the [LOCATION_008] Medicines and 
Healthcare products Regulatory  Agency , the Pharmaceuticals and Medical Devices Agency  of 
Japan). If the stud y site is contact[CONTACT_63224] a regulatory bod y, the Sponsor should 
be notified immediately . The Invest igator guarantees access for quality  assurance auditors to all 
study  documents as described in Section 12.1.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 60
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372721] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the International Council on Harm onisation (I CH) Harmonised Tripartite 
Guideline for GCP. Each investigator will conduct the study  according to applicable local or 
regional regulatory  requirements and align his or her conduct in accordance with the 
“Responsibilities of the Investigator” that are listed in Appendix A. The principles of Helsinki 
are addressed through the protocol and through appendices containing requirements for informed 
consent and investigator responsibilities.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local 
requirements of each participating region. The Sponsor or designee will require documentation 
noting all names and titles of members who make up the respective IRB or IEC. If any  member 
of the I RB or IEC has direct participation in this study , written notification regarding his or her 
abstinence from voting must also be obtained. Those Americas sites unwilling to provide names 
and titles of all members due to privacy  and conflict of interest concerns should instead provide a 
Federal Wide Assurance Number or comparable number assigned b y the Department of Health 
and Human Services.
The Sponsor or designee will supply  relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Investigator’s Brochure, a cop y of 
the ICF, and, if applicable, subject recruitment materials and/or advertisements and other 
documents required b y all applicable laws and regulations, must be submitted to a central or 
local I RB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and subject 
informed consent must be obtained and submitted to the Sponsor or des ignee before 
commencement of the study  (ie, before shipment of the Sponsor -supplied drug or study  specific 
screening activity ). The IRB or IEC approval must refer to the study  by [CONTACT_1764], 
number, and version date; identify  versions of other documents (eg, ICF) reviewed; and state the 
approval date. The Sponsor will ship drug/notify  site once the Sponsor has confirmed the 
adequacy  of site regulatory  documentation and, when applicable, the Sponsor has received 
permission from competent authority  
to begin the study . Until the site receives drug/notification 
no protocol activities, including screening, may  occur.
Sites must adhere to all requirements stipulated by  [CONTACT_1765]. This may  include 
notification to the I RB or I EC regarding protocol amendments, updates to the ICF, recruitment 
materials intended for viewing b y subjects, local safet
y reporting requirements, reports and 
updates regarding the ongoing review of the stud y at intervals specified b y the respective IRB or 
IEC, and su bmission of the investigator’s final status report to I RB or IEC. All I RB and IEC 
approvals and relevant documentation for these items must be provided to the Sponsor or its 
designee.
Subject incentives should not exert undue influence for participation. P ayments to subjects must 
be approved b y the IRB or IEC and Sponsor.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 61
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372722] authorization form (if applicable), and subject 
information sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosure
s of the subject’s personal and personal health information for purposes of conducting 
the study . The ICF and the subject information sheet (if applicable) further explain the nature of 
the study , its objectives, and potential risks and benefits, as well a s the date informed consent is 
given. The ICFwill detail the requirements of the participant and the fact that he or she is free to 
withdraw at an y time without giving a reason and without prejudice to his or her further medical 
care.
The investigator is responsible for the preparation, content, and IRB or IEC approval of the ICF
and, if applicable, the subject authorization form. The ICF, subject authorization form (if 
applicable), and subject information sheet (if applicable) must be approved by  [CONTACT_304535].
The ICF, subject authorization form (if applicable), and subject information sheet (if applicable) 
must be written in a language full y comprehensible to the prospective subject. I t is the 
responsibility  of the inve stigator to explain the detailed elements of the ICF, subject 
authorization form (if applicable), and subject information sheet (if applicable) to the subject. 
Information should be given in both oral and written form whenever possible and in the manner 
deemed appropriate b y the I RB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legall y acceptable representative may 
provide such consent for the subject in accordance with applicable laws and regulations.
The subject must be given ample opportunity  to: (1) inquire about details of the study , and 
(2)decide whether or not to participate in the study . If the subject determines he or she will 
participate in the stud y, then the ICFand subject aut horization form (if applicable) must be 
signed and dated b y the subject at the time of consent and prior to the subject entering into the 
study . The subject should be instructed to sign using their legal names, not nicknames, using blue 
or black ballpoint ink. The investigator must also sign and date the ICFand subject authorization 
(if applicable) at the time of consent and prior to subject entering into the study ; however, the 
Sponsor may  allow a designee of the investigator to sign to the extent permitted by  [CONTACT_117574].
Once signed, the original ICF, subject authorization form (if applicable), and subject information 
sheet (if applicable) will be stored in the investigator’s site file. The investigator must document 
the date the subject signs the informed consent in the subject’s medical record. Copi [INVESTIGATOR_304508], the signed subject authorization form (if applicable), and subject information sheet 
(if applicable) shall be given to the subject.
All revised ICF s must be reviewed and signed by [CONTACT_304536]. The date the revised consent was obtained should be recorded in the 
subject’s medical record, and the subject should receive a cop y of the revised ICF.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 62
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372723]’s right to protection 
against invasion of privacy . Throughout this study , a subject’s source data will only  be linked to 
the Sponsor’s clinical study  database or documentation via a unique identification number. As 
permitted by  [CONTACT_304537], limited subject attributes, such as sex, age, or 
date of birth, and subject initials may  be used to verify  the subject and accuracy  of the subject’s 
unique identification number.
To comply  with ICH Guidelines for GCP and to verify  compl iance with this protocol, the 
Sponsor requires the investigator to permit its monitor or designee’s monitor, representatives 
from an y regulatory  authority  (eg, FDA, Medicines and Healthcare products Regulatory  Agency , 
Pharmaceuticals and Medical Devices Ag ency ), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
documents), including, but not limited to, laboratory test result reports, ECG reports, admission 
and discharge sum maries for hospi[INVESTIGATOR_1684] a subject’s study  
participation, and autopsy  reports. Access to a subject’s original medical records requires the 
specific authorization of the subject as part of the informed consent process (see Section 13.2).
Copi[INVESTIGATOR_124405] y subject source documents that are provided to the Sponsor must have certain 
personall y identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s CRF).
13.[ADDRESS_372724] results and al l data derived 
by [CONTACT_87853] . During and after the study , only the Sponsor may make stud y 
information available to other study  investigators or to regulatory  agencies, except as required b y 
law or regulation. Except as otherwise allowa ble in the clinical study  site agreement, an y public 
disclosure (including publicly  accessible websites) related to the protocol or study  results, other 
than study  recruitment materials and/or advertisements, is the sole responsibility  of the Sponsor.
The Sponsor may  publish any  data and information from the study  (including data and 
information generated b y the investigator) without the consent of the investigator. Manuscript 
authorship for an y peer -
reviewed publication will appropriatel y reflect contributions to the 
production and review of the document. All publications and presentations must be prepared in 
accordance with this section and the Clinical Study Site Agreement. In the event of an y 
discrepancy  between the protocol and the Clinical Study  Site A greement, the Clinical Study  Site 
Agreement will prevail.
13.4.2 Clinical Study Registration 
In order to ensure that information on clinical trials reaches the public in a timely  manner and to 
comply  with applicable laws, regulations and guidance, [COMPANY_005] will, a t a minimum register all 
interventional clinical trials it sponsors any where in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of stud y, as defined in [COMPANY_005] Policy/Standard. [COMPANY_005] 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 63
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372725] information, along with in vestigator’s city , state (for Americas investigators), country , 
and recruiting status will be registered and available for public viewing. 
For some registries, [COMPANY_005] will assist callers in locating stud y sites closest to their homes by 
[CONTACT_304538], address, and phone number to the callers requesting trial 
information. Once subjects receive investigator contact [CONTACT_3031], they  may  call the site 
requesting enrollment into the trial. The investigative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks additional 
questions bey ond the topic of trial enrollment, they  should be referred to the Sponsor.
Any investigator who objects to the Sponsor providing this infor mation to callers must provide 
the Sponsor with a written notice requesting that their information not be listed on the registry  
site.
13.4.[ADDRESS_372726] the results of clinical studies on ClinicalTrials.gov or other public ly accessible 
websites, as required b y [COMPANY_005] Policy /Standard, applicable laws and/or regulations.
13.[ADDRESS_372727] i s participating. If a local underwriter is required, then the Sponsor or 
Sponsor’s designee will obtain clinical study  insurance against the risk of injury  to study  
subjects. Refer to the study  site agreement regarding the Sponsor’s policy  on subject 
compe nsation and treatment for injury . If the investigator has questions regarding this policy , he 
or she should contact [CONTACT_13679]’s designee.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 64
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372728] Ty pe / Role Contact
[CONTACT_304539], Inc.
Fax: [PHONE_048]
Email: [EMAIL_5971]
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 65
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372729] read and that I understand this protocol, 
the Investigator’s Brochure, 
package insert and an y other product information provided b y the Sponsor. I  agree to conduct 
this study  in accordance with the requirements of this protocol and also to protect the rights, 
safet y, privacy , and well -being of study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Council on Harmonisation, E6 Good Clinical Practice: Consolidated Guideline.
All applicable laws and regulations, incl uding, without limitation, data privacy  laws and 
regulations.
Regulatory  requirements for reporting SAEs defined in Section 10.2.9 of this protocol.
Terms outlined in the study site agreement.
Responsibilities of the Investigator (Appendix A).
I further authorize that my  personal information may  beprocessed and transferred in accordance 
with the uses contemplated in Appendix Cof this protocol.
Signature [CONTACT_178088] (print or ty pe)
Investigator’s Title
Location of Facility  (City , State/Provence)
Location of Facility  (Country )
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 66
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372730] of Abbreviations
µg Microgram(s)
1,25(OH) 2D3 1,25-dihydroxyvitamin D [ADDRESS_372731] Aspartate aminotransferase
AUC Area under the concentration -time curve
AUC  The area under the concentration -time curve, from time 0 to infinity
AUC extrap% Percent of AUC extrapolated
AUC [ADDRESS_372732] research organization
CRU Clinical Research Unit
ECG Electrocardiogram
EU European Union
FDA Food and Drug Administration
FSH Follicle stimulating hormone
g Gram
GCP Good Clinical Practice
HBsAg Hepatitis B surface antigen
hCG Human chorionic gonadotropin
HCV Hepatitis C virus 
HIV Human immunodeficiency virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 67
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
IEC Independent Ethics Committee
Ig Immunoglobulin(s)
INR International normalized ratio
IRB Institutional Review Board
ISCV Intra -subject coefficient of variation
kg Kilogram
L Liter
LFT Liver function test
ln Natural log
LSM Least -squares means
m2Meters squared
MedDRA®Medical Dictionary for Regulatory Activities®
mL Milliliter
mmHg Millimeter of mercury
msec Millisecond
oz Ounce
PK Pharm acokinetic(s)
PTE Pretreatment event
PTH Parathyroid hormone
QD Once daily
QTcF QT interval corrected for heart rate using Fridericia’s formula
rhPTH Recombinant human parathyroid hormone
SAE Serious adverse event
SAP Statistical analysis plan
SC Subcutaneous
S[LOCATION_003]R Suspected unexpected serious adverse reaction
t½z Term inal disposition phase half -life
T4 Thyroxine
TEAE Treatment- emergent adverse event
tlast Time of the last measurable concentration
tmax Time of first occurrence of C max
TSH Thyroid stimulating hormone
ULN Upper limit of normal
US [LOCATION_002]
[LOCATION_003] [LOCATION_002] of America
WHO World Health Organization
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 68
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
15. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_304509]. AEs, medical history, and concurrent conditions will be coded using the MedDRA®. Drugs 
will be coded using the WHO Drug Dictionary .
15.1 CRFs (Electronic and Paper)
Completed CRFs are required for each subject who signs 
an informed consent.
The Sponsor or its designee will supply investigative sites with access to CRFs. The Sponsor will 
make arrangements to train appropriate site staff in the use of the CRF. These forms are used to 
transmit the information collected in th e performance of this study  to the Sponsor and regulatory  
authorities. CRFs must be completed in English. Data are transcribed directly  onto CRFs.
After completion of the entry  process, computer logic checks will be run to identify  items, such 
as inconsist ent dates, missing data, and questionable values. Queries may  be issued by  [CONTACT_1748] (or designees) and will be answered b y the site. 
Corrections are recorded in an audit trail that captures the old information, the new information, 
identification of the person making the correction, the date the correction was made, and the 
reason for change. Reasons for significant corrections should additionally  be included. 
The principal investigator [INVESTIGATOR_304510] s ign 
and date the appropriate CRFs as indicated. Furthermore, the investigator must retain full 
responsibility
 for the accuracy  and authenticit y of all data entered on the CRFs .
After the l ock of the c linical study database, any change of, modification of, or addition to the 
data on the CRFs should be made b y the investigator with use of change and modification 
records of the CRFs. The principal investigator [INVESTIGATOR_304511] , and must sign and date
. 
CRFs will be revi ewed for completeness and acceptability  at the study  site during periodic visits 
by [CONTACT_39810]. The Sponsor or its designee will be permitted to review the subject’s medical 
and hospi[INVESTIGATOR_304512] e accuracy  of the CRFs. The completed CRFs 
are the sole propert y of the Sponsor and should not be made available in any form to third 
parties, except for authorized representatives of appropriate governmental health or regulatory  
authorities, without written permission of the Sponsor.
15.[ADDRESS_372733] Retention
The investigator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal health information (if separate from the ICF s), electronic cop y of CRFs, including the 
audit trail, and detailed records of drug disposition to enable evaluations or audits from 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 69
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372734]’s chart to ensure long-term legibility. Furthermore, ICH E6 Section 4.9.5 requires 
the investigator to retain essential docum ents specified in I CH E6 (Section 8) until at least 
2years after the last approval of a marketing application for a specified drug indication being 
investigated or, if an application is not approved, until at least 2 years after the investigation is 
discontinued and regulatory  authorities are notified. I n ad
dition, I CHE6 Section 4.9.5 states that 
the study  records should be retained until an amount of time specified by  [CONTACT_304540] a time specified in the Clinical Study  Site Agreement between the 
investigator and Sponsor.
Refer t o the Clinical Study  Site Agreement for the Sponsor’s requirements on record retention. 
The investigator and the head of the institution should contact [CONTACT_304541] y such documents.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 70
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
16. REFERENCES
Brown, E. 1994. Homeostatic mechanisms regulating extracellular and intracellular calcium 
metabolism. In:Bilezikian, J., Marcus, R. & Levine, M. (eds.) The Parathyroids. Raven 
Press.
Goltzman, D. and Cole, D. 2006. Hy poparathy roidism. In:Favus , M. (ed.) Primer on the 
Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed.: American 
Society  for Bone and Mineral Research.
Natpara® [parath yroid hormone] 2020. Full Prescribing Information. (electronic monograph; 
document revised: 06/20 20). Available at 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125511s020lbl.pdf. [COMPANY_005] 
Pharmaceutical Company Limited.
Schuirmann, D. J. 1987. A comparison of the two one -
sided tests procedure and the power 
approach for assessing the equivalence of average bioavailability . J Pharmacokinet 
Biopharm, 15, 657-80.
Shoback, D. 2008. Hy poparathy roidism. N Engl J Med, 359, 391-403.
Silver, J. and Kronenberg, H. 1996. Parath yroid hormone -molecular biology  and regulation. 
In:
Bilezikian, J. P., Raisz , L. & Rodan, G. (eds.) Principles of Bone Biology. Academic 
Press.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 71
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372735] to I CH GCP and all the applicable 
local laws and regulations. 
The responsibilities imposed on investigators b y the FDA are 
summarized in the “Statement of Investigator” (Form FDA 1572), which must be completed and 
signed before the investigator may  participate in this study .
The investigator agrees to assume the following responsibilities by  [CONTACT_2960] a Form FDA 1572:
1.Conduct the study  in accordance with the protocol.
2.Personally  cond uct or supervise the staff that will assist in the protocol.
3.If the Investigator/institution retains the services of any  individual or part y to perform 
trial-related duties and functions, the investigator/institution should ensure that this 
individual or party  is qualified to perform those trial -related duties and functions and should 
implement procedures to ensure the integrit y of the trial -related duties and functions 
performed and an y data generated.
4.Ensure that study  related procedures, including study  specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of 
written approval from relevant governing bodies/authorities.
5.Ensure that all colleagues and employ ees assisting in the conduct of the study  are informed 
of these obligations.
6.Secure prior approval of the study  and any  changes by  [CONTACT_4215]/IEC that conform 
to 21 CFR Part 56, I CH, and local regulatory  requirements.
7.
Ensure that the IRB/IEC will be responsible for initial revie w, continuing review, and 
approval of the protocol. Promptly  report to the IRB/IEC all changes in research activity  and 
all anticipated risks to subjects. Make at least y early  reports on the progress of the study  to 
the IRB/IEC, and issue a final report wi thin [ADDRESS_372736]’s medical chart. Valid informed consent is the most current 
version approved b y the IRB/IEC. Each ICFshould contain a subject authorization section 
that describes the uses and disclosures of a subject’s personal information (including personal 
health information) that will take place in connection with the study . If an ICFdoes not 
include such a subject authorization, then the investigator must obtain a separate subject 
authorization form from each subject or the subject’s legall y acce ptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , including 
CRFs, hospi[INVESTIGATOR_1097], laboratory  results, etc, and maintain these data for a minimum of 
2years following notification by  [CONTACT_304542] t all investigations have been discontinued 
or that the regulatory  authority  has approved the marketing application. The investigator 
should contact [CONTACT_304543] y such 
documents.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 72
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
11.
Allow possible inspec tion and cop ying by  [CONTACT_304544] -specified essential 
documents.
12.Maintain current records of the receipt, administration, and disposition of Sponsor -supplied 
drugs, and return all unused Sponsor-supplied drugs to the Sponsor. 
13.Report adve rse reactions to the Sponsor promptly. In the event of an SAE, notify  the Sponsor 
within 24 hours.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 73
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372737]:
1.A statement that the study involves research.
2.An explanation of the purposes of the research.
3.
The expected duration of the subject’s participation.
4.A description of the procedures to be followed, including invasive procedures.
5.The identification of an y procedures that are experimental.
6.The estimated number of subjects involved in the study .
7. A description of the subject’s responsibilities.
8. A description of the conduct of the study.
9. A statement describing the treatment(s) and the prob ability  for random assignment to each 
treatment.
10.A description of the possible side effects of the treatment that the subject may  receive.
11.A description of an y reasonably  foreseeable risks or discomforts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A description of an y benefits to the subject or to others that reasonabl y may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures of approp riate alternative procedures or courses of treatment, if any , that might 
be advantageous to the subject and their important potential risks and benefits.
14.A statement describing the extent to which confidentiality  of records identify ing the subject 
will be maintained, and a note of the possibility  that regulatory  agencies, auditor(s), 
IRB/IEC, and the monitor may  inspect the records. By  [CONTACT_2960] a written ICF, the subject or 
the subject’s legall y acceptable representative is authorizing such access.
15.For resea rch involving more than minimal risk, an explanation as to whether an y 
compensation and an explanation as to whether any  medical treatments are available if injury  
occurs and, if so, what they  consist of or where further information may  be obtained.
16.The an ticipated prorated pay ment(s), if any , to the subject for participating in the study .
17.The anticipated expenses, if any , to the subject for participating in the study.
18.An explanation of whom to contact [CONTACT_39831] 
(
investigator), subject’s rights, and IRB/IEC and whom to contact [CONTACT_44751] a 
research -related injury  to the subject.
19.A statement that participation is voluntary , that refusal to participate will involve no penalt y 
or loss of benefits to which the sub ject otherwise is entitled, and that the subject or the 
subject’s legall y acceptable representative may discontinue participation at any time without 
penalty  or loss of benefits to which the subject is otherwise entitled.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 74
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372738]’s de cision to withdraw from the research and procedures for 
orderl y termination of participation by  [CONTACT_423].
21.
A statement that the subject or the subject’s legally acceptable representative will be 
informed in a timely  manner if information becomes available that may  be relevant to the 
subject’s willingness to continue participation in the study .
22.The foreseeable circumstances or reasons under which the subject’s participation in the study  
may be terminated.
23. A written subject authorization (either contained w ithin the ICF or provided as a separate 
document) describing to the subject the contemplated and permissible uses and disclosures of 
the subject’s personal information (including personal health information) for purposes of 
conducting the study. The subjec t authorization must contain the following statements 
regarding the uses and disclosures of the subject’s personal information:
a)that personal information (including personal health information) may  be processed b y or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assisting [COMPANY_005], its affiliates, and licensing 
partners; (3) regulator y agencies and other health authorities; and (4) IRBs/IECs;
b)it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same le vel of protection as the data protection laws within this country ; 
however, [COMPANY_005] will make every effort to keep your personal information confidential, 
and y our name [CONTACT_87873]  [CONTACT_2371];
c)that personal information (including personal health information) may  be added to 
[COMPANY_005]’s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safet y and effectiveness of the study medication(s), studying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency  of future 
clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study  to the extent that 
the restricted use or disclosure of such information may  impact the scientific integrit y of 
the research; and
e)that the subject’s identity will remain confidential in the event that study  results are 
published.
24.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active must use highly  effective /effective contraception (as defined in the 
informed consent) from signing the informed consent and throughout the duration of the 
study , and for 28days after the last dose of study  drug. Regular pregnancy  tests will be 
performed throughout the study  for all female subjects.
25.A statement that clinical trial information from this trial will be publicly  disclosed in a 
publicly  accessible website, such as ClinicalTrials.gov.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 75
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372739] and retain personal information of Investigator, including his or her name, 
address, and other personally  identif iable information. I n addition, investigator’s personal 
information may  be transferred to other parties located in countries throughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licen sing partners.
Business partners assisting [COMPANY_005], its affiliates, and licensing partners.
Regulatory  agencies and other health authorities.
IRBs and IECs.
Investigator’s personal information may  be retained, processed, and transferred b y [COMPANY_005] and 
these 
other parties for research purposes including the following:
Assessment of the suitability  of investigator for the study  and/or other clinical studies.
Management, monitoring, inspection, and audit of the study .
Analy sis, review, and verification of the st udy results.
Safety  reporting and pharmacovigilance relating to the study .
Preparation and submission of regulatory  filings, correspondence, and communications to 
regulatory  agencies relating to the study .
Preparation and submission of regulatory  filings, correspondence, and communications to 
regulatory  agencies relating to other medications used in other clinical studies that may  
contain the same chemical compound present in the study  medication.
Inspections and investigations by  [CONTACT_304545] y.
Self-inspection and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact [CONTACT_3031], study  details and results on publicly  accessible 
clinical tri al registries, databases, and websites.
Investigator’s personal information may  be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in investigator’s 
own country .
Investigator acknowledges and consents to the use of his or her personal information by  [CONTACT_47407].
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 76
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372740] 
dose of study  drug , female subjects of childbearing potential ** who are sexually  active with a 
nonsterilized male partner* must use a highl y effective/ effective method of contraception (from 
the list below). 
In addition they  must be advised not to donate ova during this period.
Definitions and Procedures for Contrac eption and Pregnancy  Avoidance
The following definitions apply  for contraception and pregnancy  avoidance procedures.
* Sterilized males should be at least [ADDRESS_372741] had bilateral 
orchidectom y.
** A woman is considered a woman of childbearing potential, ie,fertile, following menarche and 
until becoming post -menopausal unless permanently  sterile. Permanent sterilization methods 
include hy sterectomy , and bilateral oophorectomy. A postmenopausal state is defined as no 
menses for 12 months without an alternative medical cause. A high FSH level in the 
postmenopausal range (FSH >40 IU/L) will be used to confirm a post
-menopausal state
including in younger women (eg, those <45 year old) or women who are not using hormonal 
contraception or hormonal replacement therap y.
A female of non -childbearing potential, must have undergone one of the following sterilization 
procedures at least [ADDRESS_372742] dosing:
ohysteroscopic sterilization;
obilateral tubal ligation or bilateral salpi[INVESTIGATOR_8820] y;
ohysterectom y;
obilateral oophorectomy ;
or be postmenopausal with amenorrhea for at least [ADDRESS_372743] dosing and FSH serum 
levels consi stent with postmenopausal status. A postmenopausal state is defined as no menses for 
12 months without an alternative medical cause. A high FSH level in the postmenopausal range 
(FSH >40 IU/ L) willbe used to confirm a post- menopausal state in y ounger wome n (eg, those 
<45year old) or women who are not using hormonal contraception or hormonal replacement 
therap y. However, in the absence of 12 months of amenorrhea, a single FSH measurement is 
insufficient.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 77
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
The following procedures apply  for contraception and pregnancy  avoidance.
1.Highl y effective methods of contraception are defined as “those, alone or in combination, 
that result in a low failure rate (ie, less than 1% failure rate per year when used consistently  
and correctl y)”:
Non-Hormonal Methods: 
–Intraut erine device at least [ADDRESS_372744] dosing .
–Bilateral tubal occlusion.
–Vasectomised partner * (provided that partner is the sole sexual partner of the study
participant and that the vasectomised partner has received medical assessment of the 
surgical success
).
–True sexual abstinence, only  if this is in line with the preferred and usual lifesty le of 
the subject. True abstinence is defined as refraining from he terosexual intercourse 
during the entire period of the study , from [ADDRESS_372745] dose.
Hormonal Methods: Hormonal contraception may be susceptible to interaction with the 
investigative compound, comparator, conco mitant medications, which may reduce the 
efficacy  of the contraception method (Evaluate on compound- by-compound and protocol 
–by-protocol basis and obtain clinical pharmacology  justification).
–Combined (estrogen and progestogen) hormonal contraception asso ciated with 
inhibition of ovulation initiated at least [ADDRESS_372746] dose of study  drug 
OR combined with a barrier method (male condom, female condom or diaphragm) if 
for shorter duration until she has been on contraceptive for 3 months;
Oral.
Intravaginal (eg, ring).
transdermal.
–Progestogen -
only hormonal contraception associated with inhibition of ovulation 
initiated at least [ADDRESS_372747] dose of study  drug OR combined with a 
barrier method (male condom, female condom or diaph ragm) if shorter till she has 
been on contraceptive for 3 months;
oral.
Injectable.
Implantable.
2. E ffective methods of contraception methods of contraception are defined as “those, alone or 
in combination, that may result in a failure rate lessthan 1% ”:
Double- barrier method (contraceptive sponge, diaphragm or cervical cap with 
spermicidal jellies or creams PL US male condom).
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 78
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Progestogen onl y hormonal contraception, where inhibition of ovulation is not the 
primary  mode of action PLUS condom with or withou t spermicide.
3.Unacceptable methods of contraception are:
Periodic abstinence (eg, calendar, ovulation, sy mptothermal, post -
ovulation methods).
Spermicides only .
Withdrawal.
No method at all.
Use of female and male condoms together.
Cap/diaphragm/sponge without spermicide and without condom.
4.Subjects will be provided with information on highly effective/effective methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they  understand t he requirements for avoidance of pregnancy , 
donation of ova, {and sperm donation} during the course of the stud y.
5.During the course of the study , regular serum human chorionic gonadotropin (hCG) 
pregnancy  tests will be performed onl y for women of childbear ing potential and all subjects 
(male and female) will receive continued guidance with respect to the avoidance of 
pregnancy and sperm donation as part of the study procedures. Such guidance should include 
a reminder of the following:
a)contraceptive requirements of the study
b) reasons for use of barrier methods (ie, condom) in males with pregnant partners
c)assessment of subject compliance through questions such as
i.Have you used the contraception consistently and correctly since the last visit?
ii.Have you forgotten to use contraception since the last visit?
iii.Are your menses late (even in women with irregular or infrequent menstrual cy cles a 
pregnancy  test must be performed if the answer is “y es”)
iv.Is there a chance you could be pregnant ?
6.In addition to a negative serumhCG pregnancy  test at Screening, female subjects of 
childbearing potential must also have confirmed menses in the month before first dosing (no 
delay ed menses ; with the exception of female subjects using a protocol acceptable 
contraception method that h as a known side effect o f delay ed or irregular menses). In 
addition, subjects must also have a negative serum hCG pregnancy  test within [ADDRESS_372748] dose of study drug, 
preferabl yon the same day .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 79
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) [ADDRESS_372749] to the Avoidance of Pregnancy
Such guidance should include a reminder of the following:
contraceptive requirements of the study .
reasons for use of barrier methods (ie, condom) in males with pregnant partners .
assessment of subject compliance through questions such as:
–Have you used the contraception consistently and correctly since the last visit?
–
Have you forgotten to use contraception since the last visit? 
–Are your menses late (even in women with irregular or infrequent menstrual cy cles a 
pregnancy  test must be performed if the answer is “y es”)
–Is there a chance you could be pregnant ?
Pregnancy
If any subject is found to be pregnant during the study she should be withdrawn and an y 
sponsor -supplied drug should be immediately  discontinued. I n addition, any  pregnancies in the 
partner of a male subject during the stud y or for [ADDRESS_372750]’s partner. 
If the female sub jectand/or fem ale partner of a male subject agrees to the primary  care phy sician 
being informed, the investigator should notify  the p rimary  care ph ysician that the female 
subject/female partner of the subject was participating in a clinical study  at the time she became 
pregnant and provide details of the study  drug the subject received (blinded or unblinded, as 
applicable).
All pregnancies, including female partners of male subjects, will be followed up to final 
outcome, using the pregnancy  form. Pregnancies will remain blinded to the study  team. The 
outcome, including an y premature termination, must be reported to the sponsor. An evaluation 
after the birth of the child will also be conducted.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 80
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Appendix ESummary of Changes from Previous Version 
The protocol is amended to address updates as requested by [CONTACT_304546] 03 Nov 2021.
A summary  of changes incorporated into Amendment 1 is provided in the table below.
Summary of Changes(s) Sinc e Last Version of Approved Protocol
Description of Change Section(s) Affected by [CONTACT_304547] 1(Study  Summary )
Section 2 (Study  Schematic)
Section 3 (Schedule of Study  Procedures)
Section 5.2.3 ( )
Section 5.3.3 ( )
Section
 6.1(Study  Design)
Section 6.4.1 (Rationale of Study  Design)
Section [IP_ADDRESS] ( ) 
(new section)
Section 7.3 (Excluded Medications, Supplements, 
Dietary  Products)
Section 9.2.8 (AE Monitoring)
Section 9.3 (Pharmacokinetics,  
Section 9.3.3 ( )(new section)
Section 9.3.6 (Confinement)
Section [IP_ADDRESS] (Collection Period)
Section [IP_ADDRESS] ( )(new section)
Section 11.1.5 ( ) (new section)
Section 14.1.4 (List of Abbreviations)
Section
 16(References)
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 81
TAK -834-1001 Protocol Amendment 1
rhPTH(1 -84) 18 Nov 2021
Summary of Changes(s) Sinc e Last Version of Approved Protocol
Description of Change Section(s) Affected by [CONTACT_304548] -adjusted Cmaxinthe primary  
endpoints of the study .Section 1(Study  Summary )
Section 5.3.1 (Primary  Endpoints)
Section 5.3.4 (Additional Endpoints)
Section [IP_ADDRESS] (Relative Bioavailability ([Part I 
(Relative Bioavailability )])
Sample size for Part I  was increased 
from [ADDRESS_372751] udy.Section 1 (Study  Summary )
Section 6.1 (Study  Design)
Section 7.7 (Subject Replacement)
Section 11.3 (Determination of Sample Size)
Resting position prior to vital signs 
measurements was updated from supi[INVESTIGATOR_304513].Section 3(Schedule of Study  Procedures)
List of prohibited medication and 
supplements was updated to align with 
the indication in the exclusion criterion.Section 7.3 (Excluded Medication, Supplements, 
Dietary  Products)
For non-commercial use only